WO2004005252A1 - Azabicyclo derivatives as muscarinic receptor antagonists - Google Patents

Azabicyclo derivatives as muscarinic receptor antagonists Download PDF

Info

Publication number
WO2004005252A1
WO2004005252A1 PCT/IB2003/001367 IB0301367W WO2004005252A1 WO 2004005252 A1 WO2004005252 A1 WO 2004005252A1 IB 0301367 W IB0301367 W IB 0301367W WO 2004005252 A1 WO2004005252 A1 WO 2004005252A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
hydroxy
formula
azabicyclo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2003/001367
Other languages
French (fr)
Inventor
Mohammad Salman
Anita Mehta
Pakala Kumara Savithru Sarma
Shankar Jayram Shetty
Sankaranarayanan Dharmarajan
Naresh Kumar
Arundutt Viswanatham Silamkoti
Anita Chugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Priority to SI200330515T priority Critical patent/SI1551803T1/en
Priority to CA002491998A priority patent/CA2491998A1/en
Priority to BR0312572-6A priority patent/BR0312572A/en
Priority to DE60309057T priority patent/DE60309057T2/en
Priority to EA200500172A priority patent/EA007932B1/en
Priority to EP03762827A priority patent/EP1551803B8/en
Priority to JP2004519035A priority patent/JP2005535655A/en
Priority to DK03762827T priority patent/DK1551803T3/en
Priority to NZ537585A priority patent/NZ537585A/en
Priority to US10/520,572 priority patent/US7544708B2/en
Priority to AU2003226579A priority patent/AU2003226579B2/en
Priority to MXPA05000435A priority patent/MXPA05000435A/en
Priority to HK06100635.5A priority patent/HK1082728B/en
Priority to EP04700287A priority patent/EP1626957A1/en
Priority to CA002522071A priority patent/CA2522071A1/en
Priority to CNB2004800144712A priority patent/CN100436414C/en
Priority to PCT/IB2004/000008 priority patent/WO2004089900A1/en
Priority to BRPI0409302-0A priority patent/BRPI0409302A/en
Priority to US10/552,503 priority patent/US20070021487A1/en
Priority to NZ542952A priority patent/NZ542952A/en
Priority to JP2006506251A priority patent/JP2006522787A/en
Priority to AU2004228452A priority patent/AU2004228452A1/en
Priority to EA200501593A priority patent/EA009387B1/en
Priority to JP2006506252A priority patent/JP2006522788A/en
Priority to AU2004228760A priority patent/AU2004228760A1/en
Priority to CA002521989A priority patent/CA2521989A1/en
Priority to BRPI0409308-9A priority patent/BRPI0409308A/en
Priority to CNA2004800145024A priority patent/CN1794985A/en
Priority to EA200501595A priority patent/EA009942B1/en
Priority to PCT/IB2004/000012 priority patent/WO2004089364A1/en
Priority to US10/552,455 priority patent/US7446123B2/en
Priority to NZ542951A priority patent/NZ542951A/en
Priority to EP04700488A priority patent/EP1620087A1/en
Publication of WO2004005252A1 publication Critical patent/WO2004005252A1/en
Anticipated expiration legal-status Critical
Priority to CY20061101846T priority patent/CY1105879T1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.
  • the invention relates to derivatives of azabicyclo compounds, including, for example, 6- substituted azabicyclo[3.1.0] hexanes, 2,6- and 4,6-disubstituted derivatives, and 2,4,6- trisubstituted derivatives, as well as pharmaceutical compositions containing such compounds and methods of treating diseases mediated through muscarinic receptors.
  • Muscarinic receptors as members of the G Protein Coupled Receptors are composed of a family of 5 receptor sub-types (Mi, M 2 , M 3 , i and M 5 ) and are activated by the neurotransmitter acetylcholine. These receptors are widely distributed on multiple organs and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission. The regional distribution of these receptor sub-types in the brain and other organs has been documented.
  • the M] subtype is located primarily in neuronal tissues such as cereberal cortex and autonomic ganglia, the M 2 subtype is present mainly in the heart where it mediates cholinergically induced bradycardia, and the M 3 subtype is located predominantly on smooth muscle and salivary glands (Nature, 323, p.411 (1986); Science, 237, p.527 (1987)).
  • Muscarinic agonists such as muscarine and pilocarpine and antagonists such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds, making it difficult to assign specific functions to the individual receptors.
  • classical muscarinic antagonists such as atropine are potent bronchodilators, their clinical utility is limited due to high incidence of both peripheral and central adverse effects such as tachycardia, blurred vision, dryness of mouth, constipation, dementia, etc.
  • azabicyclo derivatives including, for example, 6-substituted azabicyclo[3.1.0]hexanes, 2,6- and 4,6-disubstituted derivatives, and 2,4,6-trisubstituted derivatives, are provided as muscarinic receptor antagonists which can be useful as safe and effective therapeutic or prophylactic agents for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems. Also provided are processes for synthesizing such compounds.
  • compositions containing such compounds are provided together with acceptable carriers, excipients or diluents which can be useful for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems.
  • the enantiomers, diastereomers, N-oxides, polymorphs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates of these compounds as well as metabolites having the same type of activity are also provided, as well as pharmaceutical compositions comprising the compounds, their metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier and optionally included excipients.
  • Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group consisting of oxygen, sulphur and nitrogen atoms, the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C ⁇ -C 4 ), lower perhalo alkyl (C ⁇ -C 4 ), cyano, hydroxy, nitro, lower alkoxy (C ⁇ -C 4 ), lower perhalo alkoxy (C ⁇ -C 4 ), unsubstituted amino, N-lower alkyl (Ci- C 4 ) or -aryl amino, amino carbonyl, or N-lower alkyl (Cj-C 4 ) or -aryl amino carbonyl;
  • Ri represents a hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen (e.g. fluorine, chlorine, bromine and iodine);
  • R 2 represents alkyl, C -C 7 cycloalkyl ring, a C -C 7 cyclo alkenyl ring, an aryl, heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms selected from a group consisting of oxygen, sulphur and nitrogen atoms; the aryl, heteroaryl, heterocyclic or a cycloalkyl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl ( -C 4 ), lower perhalo alkyl (C ⁇ -C 4 ), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C ⁇ -C 4 ), lower perhalo alkoxy (C ⁇ -C ), unsubstituted amino, N-lower alkyl (C ⁇ -C 4 ) or -aryl amino, amino carbonyl, or N-lower alkyl (C ⁇ -C 4 ) or -
  • W represents (CH 2 ) P , wherein p represents 0 to 1 ;
  • X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen or (C ⁇ - 6 ) alkyl;
  • Y represents CHR 5 CO or (CH )q wherein R 5 represents hydrogen or methyl and q represents 0 to 4;
  • Z represents oxygen, sulphur, or NR 10 , wherein R ⁇ 0 represents hydrogen, or C ⁇ -6 alkyl;
  • Q represents (CH 2 ) n (wherein n represents 0 to 4), CHR 8 (wherein R 8 represents H, OH, C ⁇ -6 , alkyl, C ⁇ - 6 alkenyl, C ⁇ - 6 alkoxy) or CH 2 CHR 9 (wherein R represents H, OH, lower alkyl (C C ) or lower alkoxy (Cj-C 4 )); and
  • R 6 and R 7 are independently selected from H, CH 3 , COOH, CONH 2 , NH 2 , and CH 2 NH 2 .
  • Formula V in accordance with a sixth aspect, there is provided a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors.
  • the method includes administration of at least one compound having the structure of Formula I.
  • a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder associated with muscarinic receptors comprising administering to a patient in need thereof, an effective amount of a muscarinic receptor antagonist compound as described above.
  • a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory system such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, and the like; urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract symptoms (LUTS), etc.; and gastrointestinal system such as irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis with compounds as described above, wherein the disease or disorder is associated with muscarinic receptors.
  • a disease or disorder of the respiratory system such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, and the like
  • urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract symptoms (LUTS), etc.
  • gastrointestinal system such as irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis with compounds as described above, wherein the disease or disorder is associated with muscarinic receptors
  • the compounds described herein exhibit significant potency in terms of their activity, as determined by in vitro receptor binding and functional assays and in vivo experiments using anaesthetized rabbits.
  • the compounds that were found active in vitro were tested in vivo.
  • Some of the compounds are potent muscarinic receptor antagonists with high affinity towards M 3 receptors. Therefore, pharmaceutical compositions for the possible treatment for the disease or disorders associated with muscarinic receptors are provided.
  • the compounds can be administered orally or parenterally.
  • the compounds of Formula I may be prepared, for example, by the reaction sequence as shown in Scheme I.
  • the preparation comprises reacting a compound of Formula VII with a compound of Formula VI, wherein
  • Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms (such as oxygen, sulphur or nitrogen atoms), where the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C ⁇ -C 4 ), lower perhalo alkyl (C ⁇ -C 4 ), cyano, hydroxy, nitro, lower alkoxy (Ci- C 4 ), lower perhalo alkoxy (C ⁇ -C 4 ), unsubstituted amino, N-lower alkyl (C ⁇ -C 4 ) or -aryl amino, amino carbonyl, or N-lower alkyl (C ⁇ -C 4 ) or -aryl amino carbonyl; Ri represents a hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen (e.g. fluorine, chlorine, bromine and iodine);
  • R 2 represents alkyl, C 3 -C 7 cycloalkyl ring, a C 3 -C 7 cyclo alkenyl ring, an aryl, heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms; the aryl, heteroaryl, heterocyclic or a cycloalkyl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C ⁇ -C 4 ), lower perhalo alkyl (C ⁇ -C 4 ), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (CrC 4 ), lower perhalo alkoxy (C ⁇ -C 4 ), unsubstituted amino, N-lower alkyl (C]-C 4 ) or -aryl amino, amino carbonyl, or N-lower alkyl (C ⁇ -C 4 ) or -aryl amino carbonyl;
  • W represents (CH 2 ) P , wherein p represents 0 to 1 ;
  • X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen or (Ci-6) alkyl;
  • Y represents CHR 5 CO or (CH 2 )q wherein R 5 represents hydrogen or methyl and q represents 0 to 4;
  • Z represents oxygen, sulphur, or NR ⁇ 0 , wherein R ]0 represents hydrogen, C] -6 or alkyl;
  • Q represents -(CH ) n - (wherein n represents 0 to 4), CHR 8 (wherein R 8 represents H, OH, Ci- 6 , alkyl, C ⁇ - 6 alkenyl, C ⁇ - 6 alkoxy) or CH CHR 9 (wherein R 9 represents H, OH, lower alkyl (C ⁇ -C 4 ) or lower alkoxy (C ⁇ -C 4 )); ⁇ and R 7 are independently selected from H, CH 3 , COOH, CONH 2 , NH 2 , and CH 2 NH 2 ; and
  • P is any protecting group for an amino group, for example, benzyl or t-butyloxy carbonyl groups.
  • the reaction between a compound of Formula VII and a compound of Formula VI can take place in the presence of a condensing agent (for example, l-(3- dimethylaminopropyl)-3 -ethyl carbodiimide hydrochloride (EDC) or 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU)), in a solvent (such as N,N-dimethylformamide, dimethylsulfoxide, toluene, or xylene, at temperatures ranging from about 0 to about 140°C), to give a protected compound of Formula VIII which on deprotection in the presence of a deprotecting agent (for example, palladium on carbon, trifluoroacetic acid (TFA) or hydrochloric acid) in an organic solvent (for example, methanol, ethanol, tetrahydrofuran or acetonitrile, at temperatures ranging from about 10 to about 50°C) gives an unprotected compound of Formula I.
  • salts examples include pharmacologically acceptable salts such as inorganic acid salts (for example, hydrochloride, hydrobromide, sulphate, nitrate and phosphate), organic acid salts (for example, acetate, tartarate, citrate, fumarate, maleate, tolounesulphonate and methanesulphonate).
  • inorganic acid salts for example, hydrochloride, hydrobromide, sulphate, nitrate and phosphate
  • organic acid salts for example, acetate, tartarate, citrate, fumarate, maleate, tolounesulphonate and methanesulphonate.
  • carboxyl groups When carboxyl groups are included in the Formula I as substituents, they may be present in the form of an alkaline or alkali metal salt (for example, sodium, potassium, calcium, magnesium, and the like).
  • alkaline or alkali metal salt for example, sodium, potassium, calcium, magnesium, and the like.
  • the compounds described herein may be administered to an animal for treatment orally, or by a parenteral route.
  • the pharmaceutical compositions described herein can be produced and administered in dosage units, each unit containing a certain amount of at least one compound described herein and/or at least one physiologically acceptable addition salt thereof.
  • the dosage may be varied over extremely wide limits as the compounds are effective at low dosage levels and relatively free of toxicity.
  • the compounds may be administered in the low micromolar concentration, which is therapeutically effective, and the dosage may be increased as desired up to the maximum dosage tolerated by the patient.
  • the compounds described herein can be produced and formulated as their enantiomers, diastereomers, N-Oxides, polymorphs, solvates and pharmaceutically acceptable salts, as well as metabolites having the same type of activity.
  • Pharmaceutical compositions comprising the molecules of Formulae I, II, III, IV and V or metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with pharmaceutically acceptable carrier and optionally included excipient can also be produced.
  • reaction mixture was treated with hydroxy benzotriazole (29.9 mmol, 4.04 gm) followed by N-methyl morpholine (54.4 mmol, 5.2 gm) was stirred at 0°C for 0.5 hours.
  • EDC l-[3-(dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (29.9mmol, 5.7 gms) was added and the reaction mixture was stirred at 0° C for 1 hour and further at room temperature (RT) overnight.
  • the reaction mixture was poured into saturated sodium bicarbonate and extracted with ethyl acetate. The organic layers were washed with water and dried over sodium sulphate and concentrated under reduced pressure.
  • Step b Preparation of (2R,2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cyclopentyI-2-phenyl acetamide
  • the mixture was cooled to room temperature and the reaction mixture was filtered through a bed of hyflo.
  • the hyflo bed was washed with methanol (75.0 ml), ethyl acetate (25. 0ml) and water (25.0 ml).
  • the filtrate was concentrated under vaccum.
  • the residue was diluted with water and pH of the resulting solution was adjusted to pH ⁇ 14 with IN NaOH.
  • the solution was extracted with ethyl acetate (2x50 ml) and the ethyl acetate layer was washed with water and brine solution.
  • the layer was dried over anhydrous Na 2 SO 4 and concentrated to give the title compound as solid in 96.2% (0.75g, 2.39 mmol) yield with >98 % purity by HPLC.
  • Step a Synthesis of (2R)-(l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-benzyi-3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide
  • Step a This compound was synthesised following the procedure of Example 1, Step a, using (2R)-2-hydroxy-2-cyclopentyl-2-phenyl acetic acid (synthesised as in Grover et. al, J. Ore. Chem.. 2000; 65:6283-6287), instead of 2-hydroxy-2-cyclopentyl-2-phenyl acetic acid.
  • Step b Synthesis of (2R)-(l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo[3.1.0]hexyl-6-
  • This compound was synthesised following the procedure of Example 1, Step b, using (2R)- (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6(aminomethyl)-yl]-2- hydroxy-2-cyclopentyl-2-phenyl acetamide instead of (2R,2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide.
  • the enantiomeric excess (ee) was determined by HPLC (Chinacel OD, mobile phase 90% hexane/10% EtOH/0.1% TFA) by observing the (S) and (R) isomers.
  • the (S) isomer elutef at approximately 11.11 min.
  • the (R) isomer eluted at approximately 11.81 min.
  • the optical purity was > 99%.
  • the compound exhibited a melting point of 150.2°C. Infrared spectral data showed ( DCM): 1653.8 cm "1 .
  • Example 2 using (2R)-(l ⁇ , 5 ⁇ , 6 ⁇ )-N-[3-azabicylo[3.1.0]hexyl-6-(aminomethyl)-yl]-2- hydroxy-2-cyclopentyl-2-phenyl acetamide instead of (2R,2S) (lot, 5 ⁇ , 6 ⁇ )-N-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide.
  • Step a Synthesis of (2S)-(l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cycIopentyl-2-phenyI acetamide
  • This compound was synthesized following the procedure of Example 1, Step a, using (2S)-2-hydroxy-2-cyclopentyl-2-phenyl acetic acid (synthesised as in Grover et. al, J. Org. Chem., 2000; 65:6283-6287), instead of 2-hydroxy-2-cyclopentyl-2-phenyl acetic acid.
  • Step b Synthesis of (2S)-(l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicycIo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyI acetamide
  • This compound was synthesized following the procedure of Example 1, Step b, using (2S)-(l ⁇ ,5 ⁇ ,6 )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6(aminomethyl)-yl]-2- hydroxy-2-cyclopentyl-2 -phenyl acetamide instead of (2R,2S) (l ⁇ ,5 ⁇ ,6 )-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2 -phenyl acetamide.
  • the ee was determined by HPLC (Chinacel OD, mobile phase 90% hexane/10% EtOH/0.1% TFA) by observing the (S) and (R) isomers.
  • the (S) isomer eluted at approximately 11.11 min.
  • the (R) isomer eluted at approximately 11.81 min.
  • the optical purity was > 99%.
  • Example 2 using (2S)-(l ⁇ , 5 ⁇ , 6 ⁇ )-N-[3-azabicylo[3.1.0]hexyl-6-(aminomethyl)-yl]-2- hydroxy-2-cyclopentyl-2-phenyl acetamide instead of (2R,2S) (l ⁇ , 5 ⁇ , 6 ⁇ )-N-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide.
  • Example 7 Preparation of (2R.
  • Step b Synthesis of (2R, 2S) 2-methoxy-2-cyclopentyl-2-phenyI acetic acid
  • Step c Preparation of (2R, 2S) (l ⁇ , 5 ⁇ , 6 ⁇ )-N-[3-benzyl-3-azabicyclo[3.1.0] hexyl-6-(aminomethyI)-yl]-2-methoxy-2-cyciopentyl-2-phenyl acetamide
  • Step d Preparation of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-methoxy-2-cyclopentyl-2-phenyl acetamide
  • Step a Synthesis of (2R, 2S)-(l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-
  • Step b Synthesis of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cycloheptyl-2-phenyl acetamide
  • This compound was synthesized following the procedure of Example 1, step b, using (2R, 2S)-(l ⁇ -5 ⁇ , 6 ⁇ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethy ⁇ )-y ⁇ ]- 2-hydroxy-2-cycloheptyl-2-phenyl acetamide instead of (2R, 2S) (l ⁇ , 5 ⁇ , 6 ⁇ )-N-[3- benzyl-3-azabicyclo[.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide in 90% yield.
  • the compound had
  • This compound was synthesized following the procedure of Example 1, step a, using (2R, 2S) 2-hydroxy-2-cyclobutyl-2-phenyl acetic acid (synthesized as per reported procedure of Saul B. Kadin and Joseph G.Cannon., J. Org. Chem., 1962; 27:240-245), instead of 2-hydroxy-2-cyclopentyl-2-phenyl acetic acid.
  • Step b Synthesis of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide
  • This compound was synthesized following the procedure of Example 1, step b, using (2R, 2S) (l ⁇ , 5 ⁇ , 6 ⁇ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]- 2-hydroxy-2-cyclobutyl-2-phenyl acetamide instead of (2R, 2S) (l ⁇ , 5 ⁇ , 6 ⁇ )-N-[3- benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide to give the title compound with 90.6% purity by HPLC.
  • Example 10 Preparation of (2R. 2S) (l ⁇ .5 ⁇ .6 ⁇ -N-[3-azabicvclo 3.1.01hexyl-6- (aminomethyl -yl ⁇
  • Step b Preparation of (2R,5R)-2-tert-butyl-5-[(lRorlS)-3-oxocyclopentyl]-5- phenyl-1 ,3-dioxalan-4-one
  • Step d Preparation of (2R)- [(lSorlR)-3,3-difluorocycIopentyl]-2- hydroxy- 2-phenyIaceticacid
  • MeOH MeOH
  • Step f Preparation of (2R)- (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-
  • Step g Synthesis of (2R) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo[3.1.0]hexyl-6-
  • Step-a Preparation of (2R,2S)-2-tert-butyl-5-[(lR or IS, 3R or 3S)-3-hydroxy cyclopentyl]-5-phenyl-l,3-dioxaIan-4-one.
  • Step-b Preparation of (2R, 2S)-2-tert-butyl-5-[lR or IS, 3R or 3S]-3- fluorocyclopentyl]-5-phenyl-l,3-dioxolan-4-one.
  • Step-c Preparation of (2R, 2S)-[(1R or IS, 3R or 3S]-3-fluorocycIopentyl]-2- hydroxy-2-phenylacetic acid.
  • the compound was synthesised following the procedure of Example 11, step-d using (2R, 2S, 5R)-2-tert-butyl-5-[(lR or IS, 3R or 3S)-3-fluorocyclopentyl]-5-phenyl- l,3-dioxolan-4-one instead of (2R, 5R)-2-tert-butyl-5-[(lR or lS)-3,3- difluorocyclopentyl]-5-phenyl- 1 ,3-dioxolan-4-one.
  • Step-d Preparation of (2R, 2S)-(l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[lR or IS, 3R or 3S]-3- fluorocyclopentyl]-2-hydroxy-2-phenyIacetamide.
  • This compound was synthesized following the procedure of Example 1, step a, using the acid synthesized in the above step-c, instead of 2-hydroxy-2-cyclopentyl-2- phenyl acetic acid.
  • Step-e Preparation of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-(3-fluorocyclopentyl)-2-phenyl acetamide
  • This compound was synthesized following the procedure of Example 1, step b, using (2R, 2S)-(l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]- 2-[lR or IS, 3R or 3S]-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide instead of (2R, 2S) (l ⁇ , 5 ⁇ , 6 ⁇ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2- hydroxy-2-cyclopentyl-2-phenyl acetamide.
  • the optical purity was 87.27% (HPLC).
  • This compound was prepared following the procedure of Example 11, by using (2R, 2S) [(l ⁇ , 5 ⁇ , 6 ⁇ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2- hydroxy-2-(3,3-difluorocyclo-pentyl)-2-phenyl acetamidejinstead of (2R) [(l ⁇ , 5 ⁇ , 6 ⁇ )-
  • Example 15 Preparation of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-r3-azabicvclor3.1.0 "
  • Step a Synthesis of (2R, 2S) (l ⁇ , 5 ⁇ , 6 ⁇ )-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate.
  • Step b Synthesis of (2R, 2S) (1 ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo [3.1.0] hexyI-6- (methyl)-yl]-2-hydroxy-2,2-diphenyl acetate
  • Step a Preparation of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide. It was prepared following the procedure of Example 1, step a by using 2-hydroxy-
  • Step b Preparation of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo [3.1.0] hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide
  • Step a Synthesis of (l ⁇ ,5 ⁇ ,6 ⁇ )-N- [3-benzyl-3-azabicyclo [3.1.0] hexyl-6-
  • Step b Preparation of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-cyclohexyl-2-phenyl acetamide
  • Step a Preparation of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-tert-butyloxycarbonyl-3- azabicyclo[3.1.0]-hexyl-6-yl methyl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide
  • Step b Preparation of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-tert-butyloxycarbonyl-3- azabicyclo[3.1.0]hexyl-6-yl methyl)-2-(3-silyltrimethyloxy)-2-cyclopentyl-2-phenyl acetamide
  • Boc-derivative 2.0 g, 4.8 mmol
  • imidazole 1.2 g, 16.9 mmol
  • trimethylsilyl chloride (1.54 ml, 12.0 mmol
  • Step c Preparation of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-tert-butyloxycarbonyl-3- azabicyclo[3.1.0]hex-6-yl methyl)-2-cyclopentyl-2-hydroxy-N-methyl-2-phenyl acetamide
  • Step d Preparation of (2R, 2S) (l ⁇ ,5 ⁇ ,6 ⁇ )-N-[3-azabicyclo[3.1.0]hex-6- ylmethyl)-2-cyclopentyl-2-hydroxy-N-methyl-2-phenyl acetamide
  • Biological Activity Radioligand Binding Assays The affinity of test compounds for M 2 and M 3 muscarinic receptor subtypes was determined by [ H]-N-methylscopolamine binding studies, using rat heart and submandibular gland, respectively, as described by Moriya et al., (Life Sci.. 1999; 64(25):2351-2358) with minor modifications as follows. The membrane preparation was done with the following modifications: a low spin step of 500g for 10 minutes at 4°C was used; the buffer was 20 mM HEPES, 10 mM EDTA, at pH 7.4; the high speed spin was done at 40,000g and the homogenate was passed through a filter gauge before any spinning.
  • the assay conditions were modified as follows: the assay volume was 250 ⁇ L; the incubation time was 3 hours; the PE concentration was 0.1%; the filtermat used was GF/B from Wallac; the scintillant used was Supermix from Wallac; the amount of scintillant was 500 ⁇ L/well; and the counter used was a 1450 microbeta PLUS, from Wallac.
  • Membrane preparation Submandibular glands and heart were isolated and placed in ice cold homogenising buffer (HEPES 20mM, lOmM EDTA, pH 7.4) immediately after sacrifice. The tissues were homogenised in 10 volumes of homogenising buffer and the homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500g for lOmin. The supernatant was subsequently centrifuged at 40,000g for 20 min. The pellet thus obtained was resuspended in same volume of assay buffer (HEPES 20 mM, EDTA 5mM, pH 7.4) and were stored at -70°C until the time of assay.
  • Ligand binding assay The compounds were dissolved and diluted in DMSO.
  • the membrane homogenates (150-250 ⁇ g protein) were incubated in 250 ⁇ l of assay buffer (HEPES 20 mM, pH 7.4) at 24-25°C for 3h. Non-specific binding was determined in the presence of 1 ⁇ M atropine. The incubation was terminated by vacuum filtration over GF/B fiber filters (Wallac). The filters were then washed with ice cold 50mM Tris HCl buffer (pH 7.4). The filter mats were dried and bound radioactivity retained on filters was counted. The IC 5Q and Kd were estimated by using the non-linear curve fitting program using G Pad Prism software.
  • Kj IC 50 /(1+L/Ka), where L is the concentration of [ 3 H]NMS used in the particular experiment.
  • pK, -[log K,]
  • Test compound and saline were infused intravenously via the femoral vein.
  • the bladder was exposed through a midline laparotomy and both the ureters were identified, carefully separated and ligated.
  • the ureters were incised proximally to allow free flow of urine from the kidney to the exterior.
  • Bladder neck was gently held and the urethra was traced and separated from the adjoining tissues.
  • PE canula was introduced into the bladder and ligated.
  • the bladder was drained and subsequently filled with 15ml of warm saline (37°C).
  • the other end of the intravesical catheter was connected to the Grass model 7D polygraph through a Statham P10 EZ pressure transducer to monitor the bladder pressure. Care was taken to keep the exposed area moist and warm. A period of 30-60 min was allowed for stabilization of parameters subsequent to surgery. Salivation response was assessed by placing preweighed absorbent cotton gauze in the buccal cavity for 2 minutes after carbachol administration.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

This invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0] hexanes, and 2,4,6-trisubstituted derivatives. The invention also relates to pharmaceutical compositions containing the compounds and the methods of treating the diseases mediated through muscarinic receptors.

Description

AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS
FIELD OF THE INVENTION
This invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6- substituted azabicyclo[3.1.0] hexanes, 2,6- and 4,6-disubstituted derivatives, and 2,4,6- trisubstituted derivatives, as well as pharmaceutical compositions containing such compounds and methods of treating diseases mediated through muscarinic receptors.
BACKGROUND OF THE INVENTION
Muscarinic receptors as members of the G Protein Coupled Receptors (GPCRs) are composed of a family of 5 receptor sub-types (Mi, M2, M3, i and M5) and are activated by the neurotransmitter acetylcholine. These receptors are widely distributed on multiple organs and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission. The regional distribution of these receptor sub-types in the brain and other organs has been documented. For example, the M] subtype is located primarily in neuronal tissues such as cereberal cortex and autonomic ganglia, the M2 subtype is present mainly in the heart where it mediates cholinergically induced bradycardia, and the M3 subtype is located predominantly on smooth muscle and salivary glands (Nature, 323, p.411 (1986); Science, 237, p.527 (1987)).
A review in Current Opinions in Chemical Biology, 3, p. 426 (1999), as well as in
Trends in Pharmacological Sciences, 22, p. 409 (2001) by Eglen et. al., describes the biological potentials of modulating muscarinic receptor subtypes by ligands in different disease conditions, such as Alzheimer's Disease, pain, urinary disease condition, chronic obstructive pulmonary disease, and the like.
A review in J. Med. Chem., 43, p. 4333 (2000), by Felder et. al. describes therapeutic opportunities for muscarinic receptors in the central nervous system and elaborates on muscarinic receptor structure and function, pharmacology and their therapeutic uses.
The pharmacological and medical aspects of the muscarinic class of acetylcholine agonists and antagonists are presented in a review in Molecules, 6, p. 142 (2001). Birdsall et. al. in Trends in Pharmacological Sciences, 22, p. 215 (2001) have also summarized the recent developments on the role of different muscarinic receptor subtypes using different muscarinic receptor of knock out mice.
Muscarinic agonists such as muscarine and pilocarpine and antagonists such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds, making it difficult to assign specific functions to the individual receptors. Although classical muscarinic antagonists such as atropine are potent bronchodilators, their clinical utility is limited due to high incidence of both peripheral and central adverse effects such as tachycardia, blurred vision, dryness of mouth, constipation, dementia, etc. Subsequent development of the quarterly derivatives of atropine such as ipratropium bromide are better tolerated than parenterally administered options, but most of these are not ideal anti-cholinergic bronchodilators, due to lack of selectivity for muscarinic receptor sub-types, resulting in dose-limiting side- effects such as thirst, nausea, mydriasis and those associated with the heart such as tachycardia mediated by the M2 receptor.
Annual Review of Pharmacological Toxicol, 4Λ, p. 691 (2001), describes the pharmacology of the lower urinary tract infections. Although anti -muscarinic agents such as oxybutynin and tolterodine that act non-selectively on muscarinic receptors have been used for many years to treat bladder hyperactivity, the clinical effectiveness of these agents has been limited due to the side effects such as dry mouth, blurred vision and constipation. Tolterodine is considered to be generally better tolerated than oxybutynin. (Steers et. al., in Curr. Opin. Invest. Drugs, 2, 268; Chappie et. al., in Urology, 55, 33; Steers et al., Adult and Pediatric Urology, ed. Gillenwatteret al., pp 1220-1325, St. Louis, MO; Mosby. 3rd edition (1996)). There remains a need for development of new highly selective muscarinic antagonists which can interact with distinct subtypes, thus avoiding the occurrence of adverse effects.
Compounds having antagonistic activity against muscarinic receptors have been described in Japanese patent application Laid Open Number 92921/1994 and 135958/1994; WO 93/16048; U.S. Patent No. 3,176,019; GB 940,540; EP 0325 571; WO 98/29402; EP 0801067; EP 0388054; WO 9109013; U.S. Patent No. 5,281,601. Also, U.S. Patent Nos. 6,174,900, 6,130,232 and 5,948,792; WO 97/45414 are related to 1,4-disubstituted piperidine derivatives; WO 98/05641 describes fiuorinated, 1,4-disubstitued piperidine derivatives; WO 93/16018 and WO96/33973 are other references of interest.
A report in J. Med. Chem., 44, p. 984 (2002), describes cyclohexylmethyl piperidinyl triphenylpropioamide derivatives as selective M3 antagonist discriminating against the other receptor subtypes.
SUMMARY OF THE INVENTION
In one aspect, azabicyclo derivatives, including, for example, 6-substituted azabicyclo[3.1.0]hexanes, 2,6- and 4,6-disubstituted derivatives, and 2,4,6-trisubstituted derivatives, are provided as muscarinic receptor antagonists which can be useful as safe and effective therapeutic or prophylactic agents for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems. Also provided are processes for synthesizing such compounds.
In another aspect, pharmaceutical compositions containing such compounds are provided together with acceptable carriers, excipients or diluents which can be useful for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems.
The enantiomers, diastereomers, N-oxides, polymorphs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates of these compounds as well as metabolites having the same type of activity are also provided, as well as pharmaceutical compositions comprising the compounds, their metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier and optionally included excipients.
Other aspects will be set forth in the description which follows, and in part will be apparent from the description or may be learnt by the practice of the invention.
In accordance with one aspect, there are provided compounds having the structure of Formula I:
Figure imgf000004_0001
Formula I and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, metabolites, wherein
Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group consisting of oxygen, sulphur and nitrogen atoms, the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (Cι-C4), lower perhalo alkyl (Cι-C4), cyano, hydroxy, nitro, lower alkoxy (Cι-C4), lower perhalo alkoxy (Cι-C4), unsubstituted amino, N-lower alkyl (Ci- C4) or -aryl amino, amino carbonyl, or N-lower alkyl (Cj-C4) or -aryl amino carbonyl;
Ri represents a hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen (e.g. fluorine, chlorine, bromine and iodine);
R2 represents alkyl, C -C7 cycloalkyl ring, a C -C7 cyclo alkenyl ring, an aryl, heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms selected from a group consisting of oxygen, sulphur and nitrogen atoms; the aryl, heteroaryl, heterocyclic or a cycloalkyl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl ( -C4), lower perhalo alkyl (Cι-C4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (Cι-C4), lower perhalo alkoxy (Cι-C ), unsubstituted amino, N-lower alkyl (Cι-C4) or -aryl amino, amino carbonyl, or N-lower alkyl (Cι-C4) or -aryl amino carbonyl;
W represents (CH2)P, wherein p represents 0 to 1 ; X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen or (Cι-6) alkyl;
Y represents CHR5CO or (CH )q wherein R5 represents hydrogen or methyl and q represents 0 to 4;
Z represents oxygen, sulphur, or NR10, wherein Rι0 represents hydrogen, or Cι-6 alkyl;
Q represents (CH2)n (wherein n represents 0 to 4), CHR8 (wherein R8 represents H, OH, Cι-6, alkyl, Cι-6 alkenyl, Cι-6 alkoxy) or CH2CHR9 (wherein R represents H, OH, lower alkyl (C C ) or lower alkoxy (Cj-C4)); and
R6 and R7 are independently selected from H, CH3, COOH, CONH2, NH2, and CH2NH2.
In accordance with a second aspect, there are provided compounds having the structure of Formula II (Formula I, when R and R7 = H) and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites, wherein Ar, Ri, R2, W, X, Y, Z and Q are as defined for Formula I.
H
Figure imgf000006_0001
Formula II
In accordance with a third aspect, there are provided compounds having the structure of Formula III (Formula I wherein W is (CH2)p where p = 0, X is no atom and Y is (CH2)q where q = 0, R6 = H, R7 = H) and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites, wherein Ar, Ri , R2, Z and Q are as defined for Formula I.
Figure imgf000006_0002
Formula III
In accordance with a fourth aspect, there are provided compounds having the structure of Formula TV (Formula I wherein W is (CH2)p where p = 0, X is no atom and Y is (CH2)q where q = 0, R6 = H, R7 = H, R2 = — ] ι ) and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites, wherein Ar, R\, Z and Q are as defined for Formula I and r is 1 to 4.
H
Figure imgf000006_0003
Formula IN In accordance with a fifth aspect, there are provided compounds having the structure of Formula V (Formula I wherein W is (CH2)p where p = 0, X is no atom and Y is (CH2)q where q=0, Re = H, R7 = H, R2 = T , Ri is hydroxy, Ar is phenyl), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites, wherein Z and Q are the same as defined for Formula I, s represents 1 or 2.
Figure imgf000007_0001
Formula V In accordance with a sixth aspect, there is provided a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors. The method includes administration of at least one compound having the structure of Formula I. In accordance with a seventh aspect, there is provided a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder associated with muscarinic receptors, comprising administering to a patient in need thereof, an effective amount of a muscarinic receptor antagonist compound as described above.
In accordance with an eighth aspect, there is provided a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory system such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, and the like; urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract symptoms (LUTS), etc.; and gastrointestinal system such as irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis with compounds as described above, wherein the disease or disorder is associated with muscarinic receptors.
In accordance with a ninth aspect, there are provided processes for preparing the compounds as described above. The compounds described herein exhibit significant potency in terms of their activity, as determined by in vitro receptor binding and functional assays and in vivo experiments using anaesthetized rabbits. The compounds that were found active in vitro were tested in vivo. Some of the compounds are potent muscarinic receptor antagonists with high affinity towards M3 receptors. Therefore, pharmaceutical compositions for the possible treatment for the disease or disorders associated with muscarinic receptors are provided. In addition, the compounds can be administered orally or parenterally.
DETAILED DESCRIPTION OF THE INVENTION
The compounds presented herein may be prepared by methods represented by the following reaction sequences:
Figure imgf000008_0001
Formula - VIII
Deprotection
Figure imgf000008_0002
Formula - 1 The compounds of Formula I may be prepared, for example, by the reaction sequence as shown in Scheme I. The preparation comprises reacting a compound of Formula VII with a compound of Formula VI, wherein
Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms (such as oxygen, sulphur or nitrogen atoms), where the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (Cι-C4), lower perhalo alkyl (Cι-C4), cyano, hydroxy, nitro, lower alkoxy (Ci- C4), lower perhalo alkoxy (Cι-C4), unsubstituted amino, N-lower alkyl (Cι-C4) or -aryl amino, amino carbonyl, or N-lower alkyl (Cι-C4) or -aryl amino carbonyl; Ri represents a hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen (e.g. fluorine, chlorine, bromine and iodine);
R2 represents alkyl, C3-C7 cycloalkyl ring, a C3-C7 cyclo alkenyl ring, an aryl, heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms; the aryl, heteroaryl, heterocyclic or a cycloalkyl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (Cι-C4), lower perhalo alkyl (Cι-C4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (CrC4), lower perhalo alkoxy (Cι-C4), unsubstituted amino, N-lower alkyl (C]-C4) or -aryl amino, amino carbonyl, or N-lower alkyl (Cι-C4) or -aryl amino carbonyl;
W represents (CH2)P, wherein p represents 0 to 1 ; X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen or (Ci-6) alkyl;
Y represents CHR5CO or (CH2)q wherein R5 represents hydrogen or methyl and q represents 0 to 4;
Z represents oxygen, sulphur, or NRι0, wherein R]0 represents hydrogen, C]-6or alkyl;
Q represents -(CH )n- (wherein n represents 0 to 4), CHR8 (wherein R8 represents H, OH, Ci-6, alkyl, Cι-6 alkenyl, Cι-6 alkoxy) or CH CHR9 (wherein R9 represents H, OH, lower alkyl (Cι-C4) or lower alkoxy (Cι-C4)); ό and R7 are independently selected from H, CH3, COOH, CONH2, NH2, and CH2NH2; and
P is any protecting group for an amino group, for example, benzyl or t-butyloxy carbonyl groups.
The reaction between a compound of Formula VII and a compound of Formula VI can take place in the presence of a condensing agent (for example, l-(3- dimethylaminopropyl)-3 -ethyl carbodiimide hydrochloride (EDC) or 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU)), in a solvent (such as N,N-dimethylformamide, dimethylsulfoxide, toluene, or xylene, at temperatures ranging from about 0 to about 140°C), to give a protected compound of Formula VIII which on deprotection in the presence of a deprotecting agent (for example, palladium on carbon, trifluoroacetic acid (TFA) or hydrochloric acid) in an organic solvent (for example, methanol, ethanol, tetrahydrofuran or acetonitrile, at temperatures ranging from about 10 to about 50°C) gives an unprotected compound of Formula I.
In the above scheme, where specific bases, condensing agents, protecting groups, deprotecting agents, solvents, catalysts, temperatures, etc. are mentioned, it is to be understood that other bases, condensing agents, protecting groups, deprotecting agents, solvents, catalysts, temperatures, etc. known to those skilled in the art may be used. Similarly, the reaction temperature and duration may be adjusted according to the desired needs. Suitable salts of the compounds represented by the Formula I were prepared so as to solubilize the compound in aqueous medium for biological evaluations, as well as to be compatible with various dosage formulations and also to aid in the bioavailability of the compounds. Examples of such salts include pharmacologically acceptable salts such as inorganic acid salts (for example, hydrochloride, hydrobromide, sulphate, nitrate and phosphate), organic acid salts (for example, acetate, tartarate, citrate, fumarate, maleate, tolounesulphonate and methanesulphonate). When carboxyl groups are included in the Formula I as substituents, they may be present in the form of an alkaline or alkali metal salt (for example, sodium, potassium, calcium, magnesium, and the like). These salts may be prepared by various techniques, such as treating the compound with an equivalent amount of inorganic or organic, acid or base in a suitable solvent.
Particular compounds are shown here:
(2R,2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- cyclopentyl-2-phenyl acetamide (Compound 1);
(2R,2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound 2);
(2R)-(lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- cyclopentyl 2-phenyl acetamide (Compound 3);
(2R)-(lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- cyclopentyl 2-phenyl acetamide hydrochloride salt (Compound 4); (2S)-(lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- cyclopentyl 2-phenyl acetamide (Compound 5);
(2S)-(lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- cyclopentyl 2-phenyl acetamide hydrochloride salt (Compound 6); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-methoxy-2- cyclopentyl-2-phenyl acetamide (Compound 7);
(2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- cycloheptyl-2-phenyl acetamide (Compound 8);
(2R, 2S) (lα,5 ,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- eye lobutyl-2-phenyl acetamide (Compound 9);
(2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- cyclobutyl-2-phenyl acetamide tartarate salt (Compound 10);
(2R) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3- difluorocyclopentyl)-2-phenyl acetamide (Compound 11); (2R, 2S) (lα,5 ,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3- fluorocyclopentyl)-2-phenyl acetamide (Compound 12);
(2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3- difluorocyclopentyl)-2-phenyl acetamide (Compound 13);
(2R, 2S) (lα,5α,6 )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3- difluorocyclopentyl)-2-phenyl acetamide tartarate salt (Compound 14);
(2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2- diphenyl acetate (Compound 15);
(2R, 2S) (lα,5 ,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2- diphenyl acetamide (Compound 16); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- cyclohexyl-2-phenyl acetamide (Compound 17) and
(2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hex-6-yl methyl)-2-cyclopentyl-2-hydroxy- N-methyl-2-phenyl acetamide (Compound 18).
Table I
Figure imgf000012_0001
H
Formula III
(Formula I, wherein W=(CH2)p where p=0, X is no atom and
Y=(CH2)q, where q=0, R6=R7=H)
Figure imgf000012_0002
Figure imgf000013_0001
Because of their valuable pharmacological properties, the compounds described herein may be administered to an animal for treatment orally, or by a parenteral route. The pharmaceutical compositions described herein can be produced and administered in dosage units, each unit containing a certain amount of at least one compound described herein and/or at least one physiologically acceptable addition salt thereof. The dosage may be varied over extremely wide limits as the compounds are effective at low dosage levels and relatively free of toxicity. The compounds may be administered in the low micromolar concentration, which is therapeutically effective, and the dosage may be increased as desired up to the maximum dosage tolerated by the patient. The compounds described herein can be produced and formulated as their enantiomers, diastereomers, N-Oxides, polymorphs, solvates and pharmaceutically acceptable salts, as well as metabolites having the same type of activity. Pharmaceutical compositions comprising the molecules of Formulae I, II, III, IV and V or metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with pharmaceutically acceptable carrier and optionally included excipient can also be produced.
Compounds such as those described in Table I, for example, can be prepared from the appropriate acetic acid, in analogy to specific examples provided below. The preparation of such acetic acids is known to those of ordinary skill in the art, and will be recognized by reference to the cited specific examples given below. Other compounds within the scope of the invention, such as those having R^ and/or R7 as methyl, carboxylic acid, amide, amino or methylamino will be readily prepared in analogy to the specific procedures given in the specific examples below, using appropriate azabicylo[3.1.0]hexanes which are synthesized using known methods. Other compounds within the scope of the invention, such as those having X as oxygen, sulfur or secondary or tertiary amine can be prepared in analogy to the specific procedures given in the specific examples below, using appropriate esters, thiocompounds, or amides which can be made by procedures known to those of ordinary skill in the art. Similarly, compounds within the scope of the invention, such as those having Y as CHR5CO where R5 is hydrogen or methyl can be made in analogy to the specific procedures given in the specific examples below, using appropriate anhydrides, imides or thioanhydrides which are made by procedures known to those of skill in the art. Other compounds within the scope of the invention, such as those having Z as oxygen, sulfur or secondary or tertiary amino can be made in analogy to the specific procedures given in the specific examples below, using appropriate starting materials which are made by procedures known to those of ordinary skill in the art.
The examples mentioned below demonstrate general synthetic procedures, as well as specific preparations of particular compounds. The examples are provided to illustrate the details of the invention and should not be constrained to limit the scope of the present invention.
EXAMPLES Various solvents, such as acetone, methanol, pyridine, ether, tetrahydrofuran, hexanes, and dichloromethane, were dried using various drying reagents according to procedures described in the literature. IR spectra were recorded as nujol mulls or a thin neat film on a Perkin Elmer Paragon instrument, Nuclear Magnetic Resonance (NMR) were recorded on a Varian XL-300 MHz instrument using tetramethylsilane as an internal standard.
Example 1: Preparation of (2R,2S) (lα,5α,6α)-N-f3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl~[-2-hvdroxy-2-cvclopentyl-2-phenyl acetamide (Compound No.l) Step a: Synthesis of (2R,2S) (lα,5α,6α)-N-[3-benzyl 3-azabicyclo[3.1.0] hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide
To a solution of (lα,5α,6α)-6-aminomethyl-3-benzyl-3-azabicylo[3.1.0]hexane (prepared as described in EP 0413455 A2) (29.9 mmol, 6.05 gm) in dimethyl formamide (100 ml) was added 2-(R,S)-hydroxy-2-cyclopentyl-2 -phenyl acetic acid (prepared following J. Amer Chem. Soc, 1953; 75:2654) (27.2 mmol, 6.0 gm) and cooled to 0°C. The reaction mixture was treated with hydroxy benzotriazole (29.9 mmol, 4.04 gm) followed by N-methyl morpholine (54.4 mmol, 5.2 gm) was stirred at 0°C for 0.5 hours. EDC (l-[3-(dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (29.9mmol, 5.7 gms) was added and the reaction mixture was stirred at 0° C for 1 hour and further at room temperature (RT) overnight. The reaction mixture was poured into saturated sodium bicarbonate and extracted with ethyl acetate. The organic layers were washed with water and dried over sodium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel 100-200 mesh) eluting compound in 93-95% purity. To obtain higher purity (about 99%) of the compound, it was triturated with toluene and filtered. Step b: Preparation of (2R,2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cyclopentyI-2-phenyl acetamide
To a solution of (2R,2S) (lα,5α,6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6- aminomethyl-yl]-2-hydroxy-2-cyclopentyl-2 -phenyl acetamide from Example 1, step a (1.0 g, 2.48 mmol) in methanol (25.0 ml), 5% Pd-C (0.2 g), (50% wet) was added under N2. Then, anhydrous ammonium formate (0.8 g, 12.38 mmol) was added under stirring and the reaction mixture was reflux ed for half an hour under the N2 atmosphere. The mixture was cooled to room temperature and the reaction mixture was filtered through a bed of hyflo. The hyflo bed was washed with methanol (75.0 ml), ethyl acetate (25. 0ml) and water (25.0 ml). The filtrate was concentrated under vaccum. The residue was diluted with water and pH of the resulting solution was adjusted to pH~14 with IN NaOH. The solution was extracted with ethyl acetate (2x50 ml) and the ethyl acetate layer was washed with water and brine solution. The layer was dried over anhydrous Na2SO4 and concentrated to give the title compound as solid in 96.2% (0.75g, 2.39 mmol) yield with >98 % purity by HPLC.
The compound exhibited a melting point of 149-151°C, and had infrared absorbance (KBr) at 3410, 2951.5, 2868.3, and 1652.5 cm"1. 1HNMR (CDC13) spectral data were as follows: δ 7.59-7.62 (m, 2H), 7.23-7.36 (m, 3H), 6.56 (brs, 1H), 3.03-3.15 (m, 3H), 2.78-2.90 (m, 4H, including OH), 1.51-1.71 (m, 8H), 1.19-1.27 (m, 4H), 0.70- 0.72 (m, 1H). The mass spectrum showed peaks at m/e of 315 (MH+), 297 (M-OH).
Example 2: Preparation of (2R.2S) (lα,5α,6α)-N-r3-azabicvclo|"3.1.0'|hexyl-6- (aminomethyl)-yll-2-hvdroxy-2-cvclopentyl -2 -phenyl acetamide. Hydrochloride salt (Compound No .2) To a solution of (2R,2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-
(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (prepared in Example 1) (0.2g, 0.637 mmole) in dichloromethane (4.0 ml), ethanolic HCL (1.45 N, 0.5 ml, 0.725 mmol) was added at room temperature and stirred for 10 minutes. At the same temperature diethyl ether (100 ml) was added to the reaction mixture, stirred for 5 minutes and concentrated under vacuum without heating. The residue was triturated with ether to get solid material. The ether layer was decanted and the solid was dried under vacuum to get the title compound as a hygroscopic solid in 94% (0.2 lg, 0.6 mmole) yield with >98% purity by HPLC. Example 3: Preparation of (2R)-(lα,5α,6αVN-r3-azabicvclor3.1.01hexyl-6- (aminomethyl)-yll-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No.3)
Step a: Synthesis of (2R)-(lα,5α,6α)-N-[3-benzyi-3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide
This compound was synthesised following the procedure of Example 1, Step a, using (2R)-2-hydroxy-2-cyclopentyl-2-phenyl acetic acid (synthesised as in Grover et. al, J. Ore. Chem.. 2000; 65:6283-6287), instead of 2-hydroxy-2-cyclopentyl-2-phenyl acetic acid. Step b: Synthesis of (2R)-(lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-
(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide
This compound was synthesised following the procedure of Example 1, Step b, using (2R)- (lα,5α,6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6(aminomethyl)-yl]-2- hydroxy-2-cyclopentyl-2-phenyl acetamide instead of (2R,2S) (lα,5α,6α)-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. The enantiomeric excess (ee) was determined by HPLC (Chinacel OD, mobile phase 90% hexane/10% EtOH/0.1% TFA) by observing the (S) and (R) isomers. The (S) isomer elutef at approximately 11.11 min. The (R) isomer eluted at approximately 11.81 min. The optical purity was > 99%. The compound exhibited a melting point of 150.2°C. Infrared spectral data showed ( DCM): 1653.8 cm"1. 'HNMR spectral data showed (CDCl3):δ 7.61 (d, J=9Hz, 2H), 7.30-7.38 (m, 2H), 6.70 (S,1H), 3.61-3.68 (m, 2H), 3.08-3.28 (m, 5H), 1.49-1.68 (m, 10H), 1.11-1.26 (m, 2H), 0.75-0.85 (m, 1H).
Example 4: Preparation of (2R)-(lα,5α.6 )-N- 3-azabicvclo[3.1.01hexyl-6- aminomethyl)-yll-2-hvdroxy-2-cvclopentyl-2-phenyl acetamide. hydrochloride salt
(Compound No.4
The hydrochloride salt was synthesised following the same procedure as in
Example 2, using (2R)-(lα, 5α, 6α)-N-[3-azabicylo[3.1.0]hexyl-6-(aminomethyl)-yl]-2- hydroxy-2-cyclopentyl-2-phenyl acetamide instead of (2R,2S) (lot, 5α, 6α)-N-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. Example 5: Preparation of ^SWlα^α.όo -N- -azabicyclorS.l.Olhexyl-ό- faminomethvD-yll-^-hvdroxy^-cvclopentyl^-phenyl acetamide (Compound No.5
Step a: Synthesis of (2S)-(lα,5α,6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cycIopentyl-2-phenyI acetamide This compound was synthesized following the procedure of Example 1, Step a, using (2S)-2-hydroxy-2-cyclopentyl-2-phenyl acetic acid (synthesised as in Grover et. al, J. Org. Chem., 2000; 65:6283-6287), instead of 2-hydroxy-2-cyclopentyl-2-phenyl acetic acid.
Step b: Synthesis of (2S)-(lα,5α,6α)-N-[3-azabicycIo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyI acetamide
This compound was synthesized following the procedure of Example 1, Step b, using (2S)-(lα,5α,6 )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6(aminomethyl)-yl]-2- hydroxy-2-cyclopentyl-2 -phenyl acetamide instead of (2R,2S) (lα,5α,6 )-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2 -phenyl acetamide. The ee was determined by HPLC (Chinacel OD, mobile phase 90% hexane/10% EtOH/0.1% TFA) by observing the (S) and (R) isomers. The (S) isomer eluted at approximately 11.11 min. The (R) isomer eluted at approximately 11.81 min. The optical purity was > 99%.
The compound exhibited a melting point of 62.6-63.3 °C. Infrared spectral data showed (KBr): 1653.7 cm"1. 1HNMR spectral data showed (CDCl3):δ 7.59-7.62 (m, 2H), 7.29-7.37 (m, 3H), 3.58-3.65 (m, 2H), 3.02-3.24 (m, 4H), 1.11-1.34 (m, 11H), 0.75-0.95 (m, 1H).
Example 6: Preparation of (2S)-(lα,5α,6α)-N-[3-azabicvclor3.1.01hexyl-6- aminomethyl -yl1-2-hvdroxy-2-cvclopentyl-2-phenyl acetamide. hydrochloride salt
(Compound No.6)
The hydrochloride salt was synthesized in 90 % yield following the procedure of
Example 2, using (2S)-(lα, 5α, 6α)-N-[3-azabicylo[3.1.0]hexyl-6-(aminomethyl)-yl]-2- hydroxy-2-cyclopentyl-2-phenyl acetamide instead of (2R,2S) (lα, 5α, 6α)-N-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. Example 7: Preparation of (2R. 2S (lα.5α.6αVN-r3-azabicyclor3.1.01hexyl-6- (aminomethyl)-yll-2-methoxy-2-cvclopentyl-2-phenyl acetamide (Compound 7) Step a: Preparation of (2R, 2S) 2-methoxy-2-cyclopentyl-2-phenyl acetic acid ethyl ester
To a cold solution of (2R, 2S) 2-hydroxy-2-cyclopentyl-2-phenyl acetic acid ethyl ester (synthesized as per J. Am. Chem. Soc, 1953; 75:2654) (4.5 mmol) in dimethyl formamide was added sodium hydride (9.08 mmol) in portions at 0°C and stirred at room temperature for 1 hr. Reaction mixture was cooled to 0°C and iodomethane (18.0 mmol) was added. Reaction mixture was then stirred at room temperature for 2 hrs. TLC showed absence of starting material. Water was added to reaction mixture extracted with ethylacetate. The organic layer dried over anhydrous sodium sulfate and concentrated. Crude compound was purified by column chromatography & desired product eluted with 2% EtOAc/Hexane.
1H NMR (CDCl3)spectral data were as follows:δ 7.47-7.36 (5H, m), 4.31 (2H, q), 3.26 (3H, s), 2.43 (1H, m), 1.66-1.46 (11H, m)
Step b: Synthesis of (2R, 2S) 2-methoxy-2-cyclopentyl-2-phenyI acetic acid
To a solution of (2R, 2S) 2-methoxy-2-cyclopentyl-2-phenyl acetic acid ethyl ester (1.8 mmol) in methanol, potassium hydroxide (KOH) (2.2 mmol) was added and the reaction mixture refluxed for 7 hrs. TLC showed presence of starting material then 3 mole equivalent KOH was added and reaction mixture refluxed for 3 hrs. TLC showed absence of starting materials. Reaction mixture was concentrated, residue was taken in water and neutralized with concentrated hydrochloric acid & extracted with ethylacetate. Organic layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain the desired compound. 1H NMR (CDCl3)spectral data were as follows:δ 7.48-7.35 (5H, m), 3.20 (3H, s), 2.94- 2.86 (1H, m), 1.86-1.50 (8H, m)
Step c: Preparation of (2R, 2S) (lα, 5α, 6α)-N-[3-benzyl-3-azabicyclo[3.1.0] hexyl-6-(aminomethyI)-yl]-2-methoxy-2-cyciopentyl-2-phenyl acetamide
This was prepared following the procedure of Example 1, step 'a' by using 2- methoxy-2-cyclopentyl-2 -phenyl acetic acid instead of 2-hydroxy-2-cyclopentyl-2 -phenyl acetic acid. Step d: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-methoxy-2-cyclopentyl-2-phenyl acetamide
This was prepared following the procedure of Example 1, step b by using (2R, 2S)
(lα, 5α, 6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-methoxy-2- cyclopentyl-2-phenyl acetamide instead of (2R, 2S) (lα, 5α, 6α)-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide
Η NMR (CDCl3)spectral data showed:δ 7.45-7.30 (5H, m), 7.03 (IH, m), 3.25-3.02 (9H, m), 2.00-0.86 (12H, m).
Example 8: Preparation of (2R, 2S) (lα,5α,6α)-N-|"3-azabicvclo|"3.1.0~lhexyl-6- (aminomethyl)-yll-2-hydroxy-2-cycloheptyl-2-phenyl acetamide (Compound 8)
Step a: Synthesis of (2R, 2S)-(lα,5α,6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-
6-(aminomethyl)-yl] -2-hydroxy-2-cycloheptyl-2-phenyl acetamide This compound was synthesized following the procedure of Example 1, step a, using (2R, 2S)-2-hydroxy-2-cycloheptyl-2 -phenyl acetic acid (synthesized as in Grover et. al, J. Org. Chem, 2000; 65:6283-6287), instead of 2-hydroxy-2-cycloρentyl-2-phenyl acetic acid.
Step b: Synthesis of (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cycloheptyl-2-phenyl acetamide
This compound was synthesized following the procedure of Example 1, step b, using (2R, 2S)-(lα-5α, 6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyι)-yι]- 2-hydroxy-2-cycloheptyl-2-phenyl acetamide instead of (2R, 2S) (lα, 5α, 6α)-N-[3- benzyl-3-azabicyclo[.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide in 90% yield. The compound had
Η NMR spectral data showed (CDCl3):δ 7.59-7.61 (m, 2H), 7.13-7.36 (m, 3H), 6.76 (brs, IH), 3.00-3.20 (m, 2H), 2.80-2.92 (m, 2H), 2.50-2.80 (m, IH), 2.40 (brs, 2H), 1.28-1.73 (m, 12H), 1.00-1.20 (m, 2H), 0.80-0.90 (m, IH). Infrared absorbence (DCM) at 1655.7 cm"1
The mass spectrum showed peaks at m/e of : 343 (MH+)
Example 9: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-azabicvclo|"3.1.0"|hexyl-6- (aminomethyl)-yll-2-hvdroxy-2-cyclobutyl-2-phenyl acetamide (Compound 9) Step a: synthesis of (2R, 2S) (lα,5α,6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl- 6-(aminomethyl)-yl] -2-hydroxy-2-cyclobutyI-2-phenyl acetamide
This compound was synthesized following the procedure of Example 1, step a, using (2R, 2S) 2-hydroxy-2-cyclobutyl-2-phenyl acetic acid (synthesized as per reported procedure of Saul B. Kadin and Joseph G.Cannon., J. Org. Chem., 1962; 27:240-245), instead of 2-hydroxy-2-cyclopentyl-2-phenyl acetic acid.
Step b: Synthesis of (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide
This compound was synthesized following the procedure of Example 1, step b, using (2R, 2S) (lα, 5α, 6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]- 2-hydroxy-2-cyclobutyl-2-phenyl acetamide instead of (2R, 2S) (lα, 5α, 6α)-N-[3- benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide to give the title compound with 90.6% purity by HPLC. 1HNMR (CDC13) spectral data were as follows: δ 7.50 (2H, m), 7.30 (3H, m), 6.60 (IH, m), 3.60-3.00 (9H, m), 2.04 (IH, m), 1.96-1.74 (6H, m), 1.45 (IH, m), 1.00 (IH, m).
Example 10: Preparation of (2R. 2S) (lα.5α.6α -N-[3-azabicvclo 3.1.01hexyl-6- (aminomethyl -yl~|-2-hvdroxy-2-cyclobutyl-2 -phenyl acetamide tartarate salt (Compound 10) To a solution of compound No. 9 in ethanol, solid tartaric acid was added and the solution was stirred for 1 hour at room temperature and the solvent was evaporated. Ether was added to it to precipitate the salt. It was washed with ether (4 times) by decanting supernatant liquid to give the salt as powder with 95.66% purity by HPLC. 1H NMR (CDC13) spectral data were as follows: δ 7.45 (2H, m), 7.21 (3H, m), 4.36 (2H, s), 3.42 (2H, m), 3.20 (3H, m), 3.05 (2H, m), 1.97 (IH, m), 1.90-1.60 (7H, m), 1.10 (IH, m).
Example 11 : Preparation of (2R (lα.5α.6α)-N- 3-azabicvclor3.1.01hexyl-6- (aminomethyl -yl]-2-hvdroxy-2-(3.3-difluoro cvclopentyl)-2 -phenyl acetamide (Compound 11) Step a: Preparation of (2R,5R)-2-tert-butyl-5-phenyl-l,3-dioxalan-4-one
The compound was synthesised following the procedure described in J. Org. Chem., 2000; 65:6283-6287. Step b: Preparation of (2R,5R)-2-tert-butyl-5-[(lRorlS)-3-oxocyclopentyl]-5- phenyl-1 ,3-dioxalan-4-one
To a suspension of compound of step a (1.36mmol) in tetrahydrofuran (THF) (12ml) was added lithium diisopropyl amide (LDA) in THF (1.5 mmol) drop wise at - 78°C under nitrogen atmosphere. The reaction mixture was stirred at the same temperature for 2 hours. A solution of 2-cyclopenten-l-one (1.52mmol) in THF (2ml) was added to the reaction mixture dropwise and stirred for additional 3hours. The reaction mixture was quenched with saturated aq.ammonium chloride solution and extracted with ethyl acetate. The organic layer was dried and the residue obtained after removing the solvents in vacuo was purified by column chromatography (100-200mesh silica gel). The product was eluted with 10% EtOAc-hexane mixture.
'HNMR(CDCl3):δ-values: 7.70-7.26 (m,5Ar-H), 5.43-5.37 (d,lH), 2.91-2.88 (m,lH), 2.37-1.77 (m,6H), 0.92 (s, 9H) IR(DCM): 1791 and 1746 cm"1 Step c: Preparation of (2R, 5R)-2-tert-butyl-5-[(lRorlS)-3,3- difluorocyclopentyl]-5-phenyI-l,3-dioxalan-4-one
To a solution of compound of step-b (lmmol) in chloroform (15ml) was added diethylamino sulphurtri fluoride (DAST), (3.3 mmol) at 0°C under nitrogen atmosphere. The reaction mixture was stirred at the same temperature for 30 minutes and then at room temperature for 3 days. After being cooled to 0°C, the reaction mixture (RM) was quenched carefully by adding water. The organic layer was separated and the aqueous layer extracted with chloroform. The combined organic layers were dried and the residue obtained after removing the solvent was purified by column chromatography (100-200 mesh size silica gel) eluting the compound with 5% EtOAc-hexane mixture. 1HNMR(CDCl3):δ-values : 7.73-7.35 (m,5Ar-H), 5.49 (s,lH), 2.86-2.82 (m,lH), 2.27- 1.80 (m,6H), 0.98 (s,H) IR(DCM): 1793 cm"1
Step d: Preparation of (2R)- [(lSorlR)-3,3-difluorocycIopentyl]-2- hydroxy- 2-phenyIaceticacid The solution of compound of step-c (lmmol) in MeOH (10ml ) was stirred with
3N aqueous sodium hydroxide solution for overnight at room temperature. The reaction mixture was concentrated under reduced pressure. The residue was diluted with water and extracted with dichloromethane. The aqueous layer was acidified with conc.hydrochloric acid and extracted with EtOAc. The organic layer was dried and concentrated under reduced pressure to give the product. m.pt. :123°C
'HNMR(CDCl3):δ-values : 7.69-7.37(m,5Ar-H) , 3.29-3.20(m,lH) , 2.39-1.68 (m,6H) Step e: Preparation of (lα,5α ,6α)-6-aminomethyl-3-benzyI-3- azabicyclo[3.1.0]hexane.
The compound was synthesised as per the procedure of EP 0413455 A2.
Step f: Preparation of (2R)- (lα,5α ,6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-
6-(aminomethyι)-yl] -2- [(1 Ror 1 S)-3,3-difluorocyclopentyl] -2- hydroxy-2- phenylacetamide.
It was prepared following the procedure of Example 1, step a, using the acid synthesized in step d instead of 2-hydroxy-2-cyclopentyl-2-phenyl acetic acid. Step g: Synthesis of (2R) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-
(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide It was prepared by following the procedure of Example 1, step b by using (2R)
(lα, 5α, 6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
(3,3-difluorocyclopentyl)-2-phenyl acetamide instead of (2R, 2S) (lα, 5α, 6α)-N-[3- benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. The optical purity is 87.27%) (HPLC). 1H NMR (CDC13) spectral data showed: δ 7.59-7.55 (2H, m), 7.35-7.31 (3H, m), 7.03
(lH, m), 3.18-3.11 (7H, m), 1.87-1.62 (9H, m).
Example 12: Preparation of (2R, 2S) (lα,5α,6α)-N-|"3-azabicvclor3.1.0"|hexyl-6-
(aminomethyl)-yll-2-hvdroxy-2-(3-fluorocyclopentyl)-2-phenyl acetamide (Compound
12) Step-a: Preparation of (2R,2S)-2-tert-butyl-5-[(lR or IS, 3R or 3S)-3-hydroxy cyclopentyl]-5-phenyl-l,3-dioxaIan-4-one.
To a solution of (2R, 2S, 5R)-2-tert-butyl-5-[(lR or lS]-3-oxocyclopentyl]-5- phenyl-l,3-dioxalan-4-one (1 mmol) in methanol (10 ml) cooled to 0°C, sodium borohydride (2 mmol) was added in small lots with stirring. The RM was stirred at 0°C for 1 hr. It was concentrated under reduced pressure and the residue diluted with water and extracted with EtOAc. The organic layer was dried and the residue obtained after the removal of solvents was purified by column chromatography (100-200 mesh silica gel) eluting the compound with 20%) EtOAc-hexane mixture.
1HNMR(CDCl3):δ-values : 7.68-7.29 (m, 5H, ArH) , 5.45 (d,lH) , 4.30 (m, IH), 3.25 (m,
IH), 2.65-2.63 (m, IH), 1.80-1.63 (m, 6H), 0.92 (s, 9H) IR(DCM): 1789 cm"1, 3386 cm"1
Step-b: Preparation of (2R, 2S)-2-tert-butyl-5-[lR or IS, 3R or 3S]-3- fluorocyclopentyl]-5-phenyl-l,3-dioxolan-4-one.
The solution of compound of step-a (1 mmol) in chloroform (10 ml) was cooled to
0°C and diethylamino sulphur trifluoride (DAST) (1.5 mmol) was added drop wise under nitrogen atmosphere. The RM was stirred at 0°C for 30 minutes and then at room temperature for 3 days. The RM was cooled and carefully quenched with aqueous ammonium chloride solution. The organic layer was separated and aqueous layer extracted with EtOAc. The combined organic layer was dried and residue obtained after removing the solvents was purified by column chromatography (100-200 mesh, silica gel) eluting the compound with 5% EtOAc-hexane mixture.
1HNMR(CDCl3):δ-values : 7.68-7.28 (m, 5H, Ar-H) , 5.46 (d,lH), 5.39 (m, IH), 2.90 (m,
IH), 1.98-1.25 (m, 6H), 0.93 (s, 9H)
Step-c: Preparation of (2R, 2S)-[(1R or IS, 3R or 3S]-3-fluorocycIopentyl]-2- hydroxy-2-phenylacetic acid. The compound was synthesised following the procedure of Example 11, step-d using (2R, 2S, 5R)-2-tert-butyl-5-[(lR or IS, 3R or 3S)-3-fluorocyclopentyl]-5-phenyl- l,3-dioxolan-4-one instead of (2R, 5R)-2-tert-butyl-5-[(lR or lS)-3,3- difluorocyclopentyl]-5-phenyl- 1 ,3-dioxolan-4-one.
1HNMR(CDCl3):δ 7.66-7.27 (m, 5Ar-H), 5.30-5.00 (m, H), 3.32-3.16 (m, IH), 2.05-1.26 (m, 6H).
ΓR(DCM): 1710 cm"1
Step-d: Preparation of (2R, 2S)-(lα,5α ,6α)-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[lR or IS, 3R or 3S]-3- fluorocyclopentyl]-2-hydroxy-2-phenyIacetamide. This compound was synthesized following the procedure of Example 1, step a, using the acid synthesized in the above step-c, instead of 2-hydroxy-2-cyclopentyl-2- phenyl acetic acid. Step-e: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-(3-fluorocyclopentyl)-2-phenyl acetamide
This compound was synthesized following the procedure of Example 1, step b, using (2R, 2S)-(lα,5α ,6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]- 2-[lR or IS, 3R or 3S]-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide instead of (2R, 2S) (lα, 5α, 6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2- hydroxy-2-cyclopentyl-2-phenyl acetamide. The optical purity was 87.27% (HPLC). Η NMR spectral data showed (CDCl3):δ 7.56 (2H, m), 7.35 (3H, m), 6.08 (IH, m), 5.30- 5.03 (IH, m), 3.27 (IH, m), 3.11 (2H, m), 2.91 (4H, m), 2.04-1.48 (9H, m), 0.71 (IH, m).
Example 13: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-azabicvclor3.1.0~lhexyl-6- (aminomethyl)-vH-2-hvdroxy-2-(3,3-difluoro cyclopentyl)-2-phenyl acetamide (Compound 13)
This compound was prepared following the procedure of Example 11, by using (2R, 2S) [(lα, 5α, 6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2- hydroxy-2-(3,3-difluorocyclo-pentyl)-2-phenyl acetamidejinstead of (2R) [(lα, 5α, 6α)-
N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3- difluorocyclo-pentyl)-2-phenyl acetamide] in step g, Example 11.
The optical purity is 83.778% (HPLC). 1H NMR spectral data showed (CDC13) δ : 7.57-7.30 (5H, m), 6.49-6.44 (IH, m), 3.33
(IH, m), 3.10 (2H, m), 6.49-6.44 (IH, m), 3.33 (IH, m), 3.10 (2H, m), 2.87 (3H, m),
2.23-1.80 (8H, m), 1.79-1.20 (2H, m)
IR (KBr) : 3410, 1654 cm"1
Example 14: Preparation of (2R, 2S) (lα.5α,6α)-N-r3-azabicyclo[3.1.01hexyl-6-
(aminomethyl)-yl1-2-hvdroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide tartarate salt (Compound 14)
To a solution of compound No. 13 in ethanol was added tartaric acid & heated the reaction mixture at 60°C for 1 hour. The reaction mixture was then concentrated under reduced pressure, added diethyl ether and the organic layer was removed to get light brown solid as the desired compound. The optical purity was found to be 98.14%
(HPLC)
Η NMR spectral data showed (CD3OD):δ 7.50 (2H, m), 7.20 (3, m), 4.40 (2H, s), 3.60-
3.00 (6H, m), 2.10-1.60 (8H, m), 1.19 (IH, m), 0.90 (IH, m). LR (KBr) : 3407, 1653 cm"1
Example 15: Preparation of (2R, 2S) (lα,5α,6α)-N-r3-azabicvclor3.1.0"|hexyl-6- (methyI)-yl"|-2-hvdroxy-2.2-diphenyl acetate (Compound 15) Step a: Synthesis of (2R, 2S) (lα, 5α, 6α)-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate.
Step (i): Preparation of (lα, 5α, 6α)-3-benzyl-6-hydroxymethyl-3- azabicyclo[3.1.0]hexane.
Synthesized as per reported procedure of EP 0413 455 A2 Step (ii): Preparation of (lα, 5α, 6α)-3-benzyl-6-(methanesulfonyloxy)methyl-3- azabicyclo[3.1.0]hexane:
A solution of the title compound of preparation of step (i) (0.203 g; 1 mmol) and triethyl amine (0.21 gms, 2 mmol) in ethyl acetate (25 ml) was cooled to -10°C and treated with methanesulfonyl chloride (0.17 gms, 1.5 mmol). After stirring for one hour at- -10°C, the reaction was poured into a saturated aqueous sodium bicarbonate solution.
The organic layer was died over sodium sulphate. Filtration and removal of solvent in vacuo provided the title compound as a yellow oil, which was used as such in the following step without further purification.
1H NMR (CDCl3):δ-values: 7.45 (m, 5H, arom.), 4.29 (s, 2H), 3.81 (m, 2H), 3.13 (m, 4H), 2.84 (s, 3H), 1.38 (m, 3H)
Step (iii): Preparation of (lα, 5α, 6α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-
(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate
To a solution of 2-hydroxy-2,2-diphenyl acetic acid (synthesized as per reported procedures in Vogel's textbook of "Practical Organic Chemistry," page 1046 (5th Ed); J Am. Chem. Soc, 1953; 75:2654 and EP 613232) (1 mmol, 0.228 gms) in xylene was added, (lα, 5α, 6α)-3-benzyl-6-(methanesulfonyloxyl) methyl-3-azabicyclo[3.1.0]hexane
(0.28 gms, 1 mmol) followed by DBU (l,8-diazabicyclo[5,4,0] undec-7-ene, (2 mmol,
0.305 gms) and the reaction mixture refluxed for 6 hrs. The RM was then washed with water, brine and dried over sodium sulphate. The solvents were evaporated and the crude compound thus obtained was purified by column chromatography (silicagel, 100-200 mesh) eluting the compound with 20-80, ethylacetate hexane.
Η NMR (CDCl3):δ - values: 7.46-7.22 (m, 15H, arom), 4.24 (s, IH), 4.11-4.09 (d, 2H),
3.56 (s, 2H), 2.91-2.89 (d, 2H), 2.31-2.29 (d, 2H), 1.67-1.62 (m, IH), 1.3 (s, 2H) LR (DCM): 1724 cm"1
Step b: Synthesis of (2R, 2S) (1 α,5α,6α)-N-[3-azabicyclo [3.1.0] hexyI-6- (methyl)-yl]-2-hydroxy-2,2-diphenyl acetate
It was debenzylated by following the procedure of Example 1, step b to give the title compound in 60% yield. IR (KBr): 1731.6 cm"1
1H NMR (CDC13) spectral data showed: δ 7.33-7.47 (m, 10H), 4.17 (d, 2H, J=6Hz), 2.72- 2.92 (m, 4H), 0.94-0.99 (m, 2H), 0.88 (t, IH), The mass spectrum showed peaks at m/e of 324 (M+l)
Example 16: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-azabicvclor3.1.0")hexyl-6- (aminomethyl)-yl~l-2-hvdroxy-2,2-diphenyl acetamide (Compound 16)
Step a: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-benzyl-3- azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide. It was prepared following the procedure of Example 1, step a by using 2-hydroxy-
2,2-diphenyl acetic acid (synthesized as per reported procedures in Vogel's textbook of "Practical Organic Chemistry," page 1046 (5th Ed), J. Am. Chem. Soc, 1953; 75:2654 and EP 613232) instead of 2-hydroxy-2-cyclopentyl-2-phenyl acetic acid.
Step b: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo [3.1.0] hexyl-6- (aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide
This compound was prepared following the procedure of Example 1, step b, using (lα,5α,6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2- diphenylacetamide instead of (2R, 2S) (lα,5α,6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl- 6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide to give the title compound in 70% yield. IR (KBr): 1658.0 cm"1
Η NMR (CDC13) spectral data showed:δ 7.34-7.44 (m, 10H), 6.53 (s, IH), 3.17-3.26 (m, 2H), 2.87-3.01 (m, 4H), 1.38 (s, 2H), 0.88 (t, IH). The mass spectra showed peaks at m/e 323 (M+l), 305 (M-OH).
Example 17: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl")-yl"|-2-hvdroxy-2-cvclohexyl-2-phenyl acetamide (Compound 17)
Step a: Synthesis of (lα,5α,6α)-N- [3-benzyl-3-azabicyclo [3.1.0] hexyl-6-
(aminomethyl)-yl] -2-hydroxy-2-cyclohexyl-2-phenyl acetamide It was prepared following the procedure of Example 1, step a by using 2-hydroxy- 2-cyclohexyl-2-phenyl acetic acid (synthesized as per the procedure described in J. Amer. Chem. Soc, 1953; 75:2654) instead of 2-hydroxy-2-cyclopentyl-2-phenyl acetic acid.
Step b: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6- (aminomethyl)-yl]-2-cyclohexyl-2-phenyl acetamide
This compound was prepared following the procedure of Example 1, step b using (2R, 2S) (lα,5α,6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2- hydroxy-2- cyclohexyl-2-phenyl acetamide instead of (2R, 2S) (lα,5α,6α)-N-[3-benzyl- 3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide to give the title compound in 80% yield. IR (KBr): 1654.7 cm"1
1H NMR (CDCl3)spectral data showed:δ 7.59-7.62 (m, 2H), 7.29-7.37 (m, 3H), 6.71 (s, IH), 3.03-3.14 (m, 2H), 2.80-2.92 (m, 4H), 2.42 (m, IH), 1.13-1.35 (m, 12H), 0.88 (m, IH) The mass spectra recorded peaks of 329 (M+l), 311 (M-OH).
Example 18: Preparation of (2R. 2S) (lα.5α.6α)-N-[3-azabicyclo[3.1.01hex-6-yl methyl - 2-cyclopentyl-2-hvdroxy-N-methyl-2 -phenyl acetamide (Compound 18)
Step a: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-tert-butyloxycarbonyl-3- azabicyclo[3.1.0]-hexyl-6-yl methyl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide
To a solution of (lα,5α,6α)-3N-benzyl-6-amino-3-azabicyclo[3.1.0] hexane (synthesized as per reported procedure of Braish T.F. et. al., Synlett, 1996; 1100) (2.5 g, 7.96 mole) in (50.0 mmol) at 0°C, triethylamine (3.9 ml, 28 mmol) and Boc-anhydride (5.2 g, 23.9 mmol) were added. The reaction mixture was stirred at 0°C for 30 minute and at room temperature for 12 hrs. Diluted with dichloromethane (50 ml) and washed with water and brine solution. Dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography using 25% ethyl acetate in hexane to give the title compound as solid in 86% (2.85 g, 6.9 mmol) yield. The compound exhibited a melting point of 179.5-182.9°C. Step b: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-tert-butyloxycarbonyl-3- azabicyclo[3.1.0]hexyl-6-yl methyl)-2-(3-silyltrimethyloxy)-2-cyclopentyl-2-phenyl acetamide To a solution of Boc-derivative (2.0 g, 4.8 mmol) in dimethylforrnamide (10.0 ml), imidazole (1.2 g, 16.9 mmol) and trimethylsilyl chloride (1.54 ml, 12.0 mmol) were added and the reaction mixture was stirred at RT for 12 hrs. Diluted with water (50.0 ml) and extracted with ethyl acetate. The ethyl acetate layer was washed with water and brine solution. Dried and concentrated. The residue was purified by column chromatography using 15% ethyl acetate in hexane to give the title compound in 85 % (2.0 g, 4.1 mmol) yield.
Step c: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-tert-butyloxycarbonyl-3- azabicyclo[3.1.0]hex-6-yl methyl)-2-cyclopentyl-2-hydroxy-N-methyl-2-phenyl acetamide
To a solution of trimethylsilyl derivative (2.0 g, 4.1 mmol) and n-tetrabutyl ammonium iodide (0.11 gm, 0.3 mmol) in dry tetrahydrofuran (THF) (20.9 ml) at 0°C, sodium hydride (0.6 g, 12.3 mmol) was added in portion and the resulting solution was stirred at 0°C for 15 minutes and allowed to cool to room temperature and stirred for 1 hours at RT. Again cooled to 0°C and methyl iodide (2.3 ml, 36.8 mmol) in dry THF (2.0 ml) was added dropwise. Stirred for 12 hrs at RT. Saturated aqueous NaHCO3 solution (10.0 ml) was added organic layer was separated and dried over anhydrous sodium sulfate. Concentrated and the residue was purified by column chromatograph using 15% ethyl acetate in hexane to give the title compound as semisolid in 61% (1.25 g, 2.49 mmol) yield.
Step d: Preparation of (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hex-6- ylmethyl)-2-cyclopentyl-2-hydroxy-N-methyl-2-phenyl acetamide
To a solution of the compound (0.2 g, 0.4 mmol) from the above step in ethanol (5.0 ml), conc.HCl was added dropwise till the pH of the reaction mixture was 2. The reaction mixture was stirred at RT for 24 hrs. Neutralized with saturated aqueous sodium bicarbonate solution. Concentrated under vacuum and the residue was taken in dichloromethane (10.0 ml) and washed with water and brine solution. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound as solid in 54% (0.07 g, 0.21 mmol) yield. m.p.: 91.5°C
1H NMR (CDCl3)spectral data showed:δ 7.29-7.42 m, 5H), 5.39 (m, IH), 2.81-3.52 (m, 10H), 1.11-1.82 (m, 12H) LR (DCM): 1621.9 cm"1
The mass spectrum showed peak of 329 (MH+).
Biological Activity Radioligand Binding Assays: The affinity of test compounds for M2 and M3 muscarinic receptor subtypes was determined by [ H]-N-methylscopolamine binding studies, using rat heart and submandibular gland, respectively, as described by Moriya et al., (Life Sci.. 1999; 64(25):2351-2358) with minor modifications as follows. The membrane preparation was done with the following modifications: a low spin step of 500g for 10 minutes at 4°C was used; the buffer was 20 mM HEPES, 10 mM EDTA, at pH 7.4; the high speed spin was done at 40,000g and the homogenate was passed through a filter gauge before any spinning. The assay conditions were modified as follows: the assay volume was 250 μL; the incubation time was 3 hours; the PE concentration was 0.1%; the filtermat used was GF/B from Wallac; the scintillant used was Supermix from Wallac; the amount of scintillant was 500 μL/well; and the counter used was a 1450 microbeta PLUS, from Wallac.
Membrane preparation: Submandibular glands and heart were isolated and placed in ice cold homogenising buffer (HEPES 20mM, lOmM EDTA, pH 7.4) immediately after sacrifice. The tissues were homogenised in 10 volumes of homogenising buffer and the homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500g for lOmin. The supernatant was subsequently centrifuged at 40,000g for 20 min. The pellet thus obtained was resuspended in same volume of assay buffer (HEPES 20 mM, EDTA 5mM, pH 7.4) and were stored at -70°C until the time of assay. Ligand binding assay: The compounds were dissolved and diluted in DMSO.
The membrane homogenates (150-250 μg protein) were incubated in 250 μl of assay buffer (HEPES 20 mM, pH 7.4) at 24-25°C for 3h. Non-specific binding was determined in the presence of 1 μM atropine. The incubation was terminated by vacuum filtration over GF/B fiber filters (Wallac). The filters were then washed with ice cold 50mM Tris HCl buffer (pH 7.4). The filter mats were dried and bound radioactivity retained on filters was counted. The IC5Q and Kd were estimated by using the non-linear curve fitting program using G Pad Prism software. The value of inhibition constant Kj was calculated from competitive binding studies by using Cheng & Prusoff equation (Biochem Pharmacol, 1973; 22:3099-3108), K, = IC50 /(1+L/Ka), where L is the concentration of [3H]NMS used in the particular experiment. pK, = -[log K,]
Functional Experiments using isolated rat bladder: Methodology: Animals were euthanized by overdose of urethane and whole bladder was isolated and removed rapidly and placed in ice cold Tyrode buffer with the following composition (mMol/L) NaCl 137; KC1 2.7; CaCl2 1.8; MgCl2 0.1; NaHCO3 11.9; NaH2PO4 0.4; glucose 5.55 and continuously gassed with 95%> O2 and 5 % CO . The bladder was cut into longitudinal strips (3mm wide and 5-6 mm long) and mounted in 10 ml organ baths at 30° C, with one end connected to the base of the tissue holder and the other end connected to a polygraph through a force displacement transducer. Each tissue was maintained at a constant basal tension of 2 g and allowed to equilibrate for 1 hour during which the PSS was changed every 15 min. At the end of equilibration period the stabilization of the tissue contractile response was assessed with 1 μmol/L of Carbachol consecutively for 2-3 times. Subsequently a cumulative concentration response curve to carbachol (10"9 mol L to 3 X 10"5 mol/L) was obtained. After several washes, once the baseline was achieved, cumulative concentration response curve was obtained in presence of NCE (NCE added 20 min. prior to the second CRC). The contractile results were expressed as %> of control E max. ED50 values were calculated by fitting a non-linear regression curve (Graph Pad Prism). pKB values were calculated by the formula pKB = - log [ (molar concentration of antagonist (dose ratio- 1))] where, dose ratio = ED50 in the presence of antagonist/ED5o in the absence of antagonist.
In vivo experiments using anesthetized rabbit: The effect of test substances was studied on carbachol evoked changes on bladder pressure, heart rate and salivation. Male rabbits weighing 1.2-3 kg were anaesthetized with urethane (1.5g/kg), and administered as a slow intravenous infusion through the marginal ear vein. The tracheae were cannulated to maintain airway patency. Blood pressure was recorded from the femoral artery by means of a Statham P10 EZ pressure transducer connected to a Grass model 7D polygraph. The heart rate was monitored by a tachograph triggered by the pulse wave of blood pressure. The other femoral artery was cannulated for the administration of carbachol. Test compound and saline were infused intravenously via the femoral vein. The bladder was exposed through a midline laparotomy and both the ureters were identified, carefully separated and ligated. The ureters were incised proximally to allow free flow of urine from the kidney to the exterior. Bladder neck was gently held and the urethra was traced and separated from the adjoining tissues. PE canula was introduced into the bladder and ligated. The bladder was drained and subsequently filled with 15ml of warm saline (37°C). The other end of the intravesical catheter was connected to the Grass model 7D polygraph through a Statham P10 EZ pressure transducer to monitor the bladder pressure. Care was taken to keep the exposed area moist and warm. A period of 30-60 min was allowed for stabilization of parameters subsequent to surgery. Salivation response was assessed by placing preweighed absorbent cotton gauze in the buccal cavity for 2 minutes after carbachol administration.
The effect of the compound on carbachol (1.5μg/kg, intrarterial) induced changes on blood pressure, heart rate and bladder pressure were observed. At least two stable responses were obtained. These responses were considered as 100%. Subsequently, effect of increasing dose of test compound or vehicle (i.v,12 to 15 min before carbachol challenge) was studied.
The change in bladder pressure, salivation and agonist induced bradycardia were expressed as %> change from pretreatment control. ID5o values (dose required to inhibit 50% of response) were calculated from non- linear curve fitting for sigmoidal dose response curve using Graph Pad Prism software and values were expressed as μg/kg . The results of the in-vitro and in-vivo tests are listed in Table II and Table III.
Table II
Figure imgf000033_0001
Table III
Figure imgf000033_0002

Claims

WE CLAIM:
1. Compounds having the structure of Formula I:
Figure imgf000034_0001
Formula - 1 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites, wherein
Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms, the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (Cι-C4), lower perhalo alkyl (Cι-C4), cyano, hydroxy, nitro, lower alkoxy (Cι-C4), lower perhalo alkoxy (d-C4), unsubstituted amino, N-lower alkyl (Cι-C ) or -aryl amino, amino carbonyl, or N-lower alkyl (C - C4) or -aryl amino carbonyl;
Ri represents a hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen;
R2 represents alkyl, C3-C cycloalkyl ring, a C -C cyclo alkenyl ring, an aryl, heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms; the aryl, heteroaryl, heterocyclic or a cycloalkyl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (Cι-C4), lower perhalo alkyl (C\- C ), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (Cι-C4), lower perhalo alkoxy (Cι-C ), unsubstituted amino, N-lower alkyl (Cι-C4) or -aryl amino, amino carbonyl, or N-lower alkyl (d-C4) or -aryl amino carbonyl;
W represents (CH )P, wherein p represents 0 to 1;
X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen or (Cι-6) alkyl;
Y represents CHR5CO or (CH2)q wherein R5 represents hydrogen or methyl and q represents 0 to 4;
Z represents oxygen, sulphur, or NRι0, wherein R)0 represents hydrogen or Cι-6 alkyl; Q represents -(CH2)n-, wherein n represents 0 to 4, CHR8, wherein R8 represents H, OH, C1-6, alkyl, Cι-6 alkenyl, or Cι-6 alkoxy, or Q represents CH2CHR , wherein R9 represents H, OH, lower alkyl (Cι-C4) or lower alkoxy (Q-C4); and
Re and R7 are independently selected from H, CH3, COOH, CONH2, NH2, and CH2NH2.
The compounds according to claim 1 having the structure of Formula II and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites.
Figure imgf000035_0001
Formula II
3. The compounds according to claim 1 having the structure of Formula III and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites.
Figure imgf000035_0002
Formula III
4. The compounds according to claim 1 having the structure of Formula IV and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites, wherein r is 1 to 4.
Figure imgf000035_0003
Formula IV
5. The compounds according to claim 1 having the structure of Formula V, and their pharmaceutically acceptable salts, esters, enantiomers, N-oxides, or metabolites; wherein s represents 1 to 2.
Figure imgf000036_0001
Formula V
6. A compound selected form the group consisting of
(2R,2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)- yl]-2-hydroxy-2- cyclopentyl-2-phenyl acetamide (Compound 1); (2R,2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)- yl]-2-hydroxy-2- cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound 2); (2R)-(lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl] ■2-hydroxy-2- cyclopentyl 2-phenyl acetamide (Compound 3); (2R)-(lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl] ■2-hydroxy-2- cyclopentyl 2-phenyl acetamide hydrochloride salt (Compound 4); (2S)-(lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]- 2-hydroxy-2- cyclopentyl 2-phenyl acetamide (Compound 5); (2S)-(lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]- 2-hydroxy-2- cyclopentyl 2-phenyl acetamide hydrochloride salt (Compound 6); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl) -yl] -2-methoxy-2- eye lopentyl-2 -phenyl acetamide (Compound 7); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl) -yl]-2-hydroxy-2- eye loheptyl-2 -phenyl acetamide (Compound 8); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl) -yl]-2-hydroxy-2- cyclobutyl-2-phenyl acetamide (Compound 9); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomefhyl) ■yl]-2-hydroxy-2- cyclobutyl-2 -phenyl acetamide tartarate salt (Compound 10); (2R) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]- 2-hydroxy-2-(3,3- difluorocyclopentyl)-2-phenyl acetamide (Compound 11); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl) •yl]-2-hydroxy-2- (3-fluorocyclopentyl)-2-phenyl acetamide (Compound 12); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl) •yl]-2-hydroxy-2- (3,3-difluorocyclopentyl)-2-phenyl acetamide (Compound 13); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- (3,3-difluorocyclopentyl)-2-phenyl acetamide tartarate salt (Compound 14); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy- 2,2-diphenyl acetate (Compound 15); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy- 2,2-diphenyl acetamide (Compound 16); (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2- cyclohexyl-2-phenyl acetamide (Compound 17) and (2R, 2S) (lα,5α,6α)-N-[3-azabicyclo[3.1.0]hex-6-ylmethyl)-2-cyclopentyl-2- hydroxy-N-methyl-2-phenyl acetamide (Compound 18). 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1, 2, 3, 4, 5 or 6 together with pharmaceutically acceptable carriers, excipients or diluents. 8. A method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, comprising administering to said animal or human, a therapeutically effective amount of a compound having the structure of Formula I,
Figure imgf000037_0001
Formula I its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs or metabolites, wherein Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms, wherein the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (Cι-C4), lower perhalo alkyl (Cj- C4), cyano, hydroxy, nitro, lower alkoxy (Cι-C4), lower perhalo alkoxy (Cι-C4), unsubstituted amino, N-lower alkyl (Cι-C ) or -aryl amino, amino carbonyl, or N- lower alkyl (CpC4) or -aryl amino carbonyl; Ri represents a hydrogen, hydroxy, hydroxy methyl, amino, alkoxy , carbamoyl or halogen; R2 represents alkyl, C3-C7 cycloalkyl ring, a C -C7 cyclo alkenyl ring, an aryl, heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms; the aryl, heteroaryl, heterocyclic or a cycloalkyl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (Cι-C4), lower perhalo alkyl (Q- C4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (CrC4), lower perhalo alkoxy (Cι-C4), unsubstituted amino, N-lower alkyl (Cj-C4) or -aryl amino, amino carbonyl, or N-lower alkyl (C]-C4) or -aryl amino carbonyl; W represents (CH2)P, wherein p represents 0 to 1 ; X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen or (C 6) alkyl; Y represents CHR5CO or (CH )q wherein R5 represents hydrogen or methyl and q represents 0 to 4; Z represents oxygen, sulphur, or NR10, wherein Rι0 represents hydrogen or Cι-6 alkyl; Q represents -(CH2)n-, wherein n represents 0 to 4, CHR8, wherein R8 represents H, OH, Cι-6, alkyl, Cι-6 alkenyl, Cι-6 alkoxy, or Q represents CH2CHR9, wherein R9 represents H, OH, lower alkyl (Cι-C4) or lower alkoxy (C]-C4); and Rό and R7 are independently selected from H, CH3, COOH, CONH2, NH2, CH2NH2. The method according to claim 8 for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, comprising administering to said animal or human, a therapeutically effective amount of a compound having the structure of Formula II, its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs or metabolites.
H
Figure imgf000038_0001
Formula II
10. The method according to claim 8 for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, comprising administering to said animal or human, a therapeutically effective amount of a compound having the structure of Formula III, its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites.
H
Figure imgf000039_0001
Formula III
11. The method according to claim 8 for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, comprising administering to the said animal or human, a therapeutically effective amount of a compound having the structure of Formula IN, its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, Ν-oxides, polymorphs, prodrugs or metabolites, wherein r is 1 to 4.
Figure imgf000039_0002
Formula IV
12. The method according to claim 8 for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, comprising administering to said animal or human, at least one therapeutically effective amount of a compound having the structure of Formula V, its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs or metabolites, wherein s represents 1 to 2.
Figure imgf000040_0001
Formula V 13. The method according to claim 8 wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fbrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal hyperkinesis. 14. The method according to claim 9 wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal hyperkinesis. 15. The method according to claim 10 wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal hyperkinesis. 16. The method according to claim 11 wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary frbrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal hyperkinesis. 17. The method according to claim 12 wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal. 18. The method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastroinstestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, comprising administering to said animal or human, a therapeutically effective amount of the pharmaceutical composition according to claim 7. 19. The method according to claim 18 wherein the disease or disorder urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary frbrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal hyperkinesis. 20. A method of preparing a compound of Formula I,
Figure imgf000041_0001
Formula I and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs or metabolites, wherein Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms, wherein the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (Cι-C4), lower perhalo alkyl (Ci- C4), cyano, hydroxy, nitro, lower alkoxy (Cι-C4), lower perhalo alkoxy (Cι-C4), unsubstituted amino, N-lower alkyl (Cι-C4) or -aryl amino, amino carbonyl, or N- lower alkyl (Cι-C4) or -aryl amino carbonyl; R\ represents a hydrogen, hydroxy, hydroxy methyl, amino, alkoxy , carbamoyl or halogen; R2 represents alkyl, C3-C cycloalkyl ring, a C3-C7 cyclo alkenyl ring, an aryl, heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms selected from a group consisting of oxygen, sulphur and nitrogen atoms; the aryl, heteroaryl, heterocyclic or a cycloalkyl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (Cι-C4), lower perhalo alkyl (Cι-C4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (Cι-C4), lower perhalo alkoxy (Cι-C4), unsubstituted amino, N-lower alkyl (Cι-C4) or -aryl amino, amino carbonyl, or N-lower alkyl (d-C4) or -aryl amino carbonyl; W represents (CH2)P, wherein p represents 0 to 1 ; X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen or (Cι-6) alkyl; Y represents CHR5CO or (CH2)q wherein R5 represents hydrogen or methyl and q represents 0 to 4;
Z represents oxygen, sulphur, NR10, wherein Rio represents hydrogen, Cι-6 alkyl;
Q represents (CH2)n (wherein n represents 0 to 4), CHR8 (wherein R8 represents H, OH, Cι-6, alkyl, Cι-6 alkenyl, Cι-6 alkoxy) or CH2CHR9 (wherein R9 represents H, OH , lower alkyl (Cι-C4) or lower alkoxy (Cj-C4)); and
Re and R7 are independently selected from H, CH3, COOH, CONH2, NH2, CH2NH2; said method comprising:
(a) reacting a compound of Formula VII with a compound of Formula VI
Figure imgf000042_0001
Formula VII Formula VI to give a protected compound of Formula VIII wherein Ar, Rl 5 R2, W, X, Y, Z, and Q are as defined, and P is a protecting group for an amino group
Figure imgf000042_0002
Formula VIII
(b) deprotecting the compound of Formula VIII in the presence of a deprotecting agent to give compound of Formula I wherein Ar, Ri, R , W , X, Y, Z, and Q are as defined,
Figure imgf000042_0003
21. The method of claim 20, wherein P is any protecting group for an amino group and is selected from the group consisting of benzyl and t-butyloxy carbonyl groups.
22. The method of claim 20, wherein the reaction of a compound of Formula VI with a compound of Formula VII to give a compound of Formula VIII is carried out in the presence of a condensing agent which is selected from the group consisting of l-(3- dimethyl amino prop yl)-3 -ethyl carbodiimide hydrochloride (EDC) and 1,8- diazabicyclo [5.4.0]undec-7-ene (DBU). 23. The method of claim 20, wherein the reaction of a compound of Formula VI with a compound of Formula VII is carried out in a suitable polar aprotic solvent selected from the group consisting of N,N-dimethylformamide, dimethyl sulfoxide, toluene, and xylene. 24. The method of claim 20, wherein the reaction of compound of Formula VI with a compound of Formula VII is carried out at 0-140°C. 25. The method of claim 20, wherein the deprotection of a compound of Formula VIII is carried out with a deprotecting agent which is selected from the group consisting of palladium on carbon, trifluoroacetic acid (TFA) and hydrochloric acid. 26. The method of claim 20, wherein the deprotection of a compound of Formula VIII to give a compound of Formula I is carried out in a suitable organic solvent selected from the group consisting of methanol, ethanol, tetrahydrofuran and acetonitrile.
PCT/IB2003/001367 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists Ceased WO2004005252A1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
SI200330515T SI1551803T1 (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists
CA002491998A CA2491998A1 (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists
BR0312572-6A BR0312572A (en) 2002-07-08 2003-04-11 Azabicyclic derivatives as muscarinic receptor antagonists
DE60309057T DE60309057T2 (en) 2002-07-08 2003-04-11 AZABICYCLODERIVATES AS ANTAGONISTS OF THE MUSCARIN RECEPTOR
EA200500172A EA007932B1 (en) 2002-07-08 2003-04-11 Azabicyclo derivatives derivatives as muscarinic receptor antagonists
EP03762827A EP1551803B8 (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists
JP2004519035A JP2005535655A (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists
DK03762827T DK1551803T3 (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists
NZ537585A NZ537585A (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists
US10/520,572 US7544708B2 (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists
AU2003226579A AU2003226579B2 (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists
MXPA05000435A MXPA05000435A (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists.
HK06100635.5A HK1082728B (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists
BRPI0409302-0A BRPI0409302A (en) 2003-04-11 2004-01-06 azabicyclic derivatives as muscarinic receptor antagonists, method for their preparation and pharmaceutical composition containing them
CA002522071A CA2522071A1 (en) 2003-04-11 2004-01-06 Azabicyclo derivatives as muscarinic receptor antagonists
CNB2004800144712A CN100436414C (en) 2003-04-11 2004-01-06 Azabicyclic derivatives as muscarinic receptor antagonists
PCT/IB2004/000008 WO2004089900A1 (en) 2003-04-11 2004-01-06 Azabicyclo derivatives as muscarinic receptor antagonists
EP04700287A EP1626957A1 (en) 2003-04-11 2004-01-06 Azabicyclo derivatives as muscarinic receptor antagonists
US10/552,503 US20070021487A1 (en) 2003-04-11 2004-01-06 Azabicyclo derivatives as muscarinic receptor antagonists
NZ542952A NZ542952A (en) 2003-04-11 2004-01-06 Azabicyclo derivatives as muscarinic receptor antagonists
JP2006506251A JP2006522787A (en) 2003-04-11 2004-01-06 Azabicyclo derivatives as muscarinic receptor antagonists
AU2004228452A AU2004228452A1 (en) 2003-04-11 2004-01-06 Azabicyclo derivatives as muscarinic receptor antagonists
EA200501593A EA009387B1 (en) 2003-04-11 2004-01-06 Azabicycloderivatives as muscarinic receptor antagonists
US10/552,455 US7446123B2 (en) 2003-04-11 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists
JP2006506252A JP2006522788A (en) 2003-04-11 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists
CA002521989A CA2521989A1 (en) 2003-04-11 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists
BRPI0409308-9A BRPI0409308A (en) 2003-04-11 2004-01-07 azabicyclic derivatives as muscarinic receptor antagonists, pharmaceutical composition and processes for their preparation
CNA2004800145024A CN1794985A (en) 2003-04-11 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists
EA200501595A EA009942B1 (en) 2002-07-08 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists
PCT/IB2004/000012 WO2004089364A1 (en) 2003-04-11 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists
AU2004228760A AU2004228760A1 (en) 2003-04-11 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists
NZ542951A NZ542951A (en) 2003-04-11 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists
EP04700488A EP1620087A1 (en) 2003-04-11 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists
CY20061101846T CY1105879T1 (en) 2002-07-08 2006-12-21 AZADICYCLE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2002/002663 WO2004004629A2 (en) 2002-07-08 2002-07-08 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
IBPCT/IB02/02663 2002-07-08

Publications (1)

Publication Number Publication Date
WO2004005252A1 true WO2004005252A1 (en) 2004-01-15

Family

ID=30011691

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2002/002663 Ceased WO2004004629A2 (en) 2002-07-08 2002-07-08 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
PCT/IB2003/001367 Ceased WO2004005252A1 (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/002663 Ceased WO2004004629A2 (en) 2002-07-08 2002-07-08 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists

Country Status (19)

Country Link
US (2) US7399779B2 (en)
EP (2) EP1546099B1 (en)
JP (2) JP2006502985A (en)
CN (2) CN1668585A (en)
AT (2) ATE419236T1 (en)
AU (2) AU2002345266B2 (en)
BR (2) BR0215801A (en)
CA (2) CA2492121A1 (en)
CY (1) CY1105879T1 (en)
DE (2) DE60230683D1 (en)
DK (1) DK1551803T3 (en)
EA (3) EA200500173A1 (en)
ES (1) ES2274275T3 (en)
MX (2) MXPA05000434A (en)
NZ (2) NZ537584A (en)
PT (1) PT1551803E (en)
SI (1) SI1551803T1 (en)
WO (2) WO2004004629A2 (en)
ZA (1) ZA200500951B (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032994A3 (en) * 2004-09-24 2006-05-04 Ranbaxy Lab Ltd Muscarinic receptor antagonists
WO2006035282A3 (en) * 2004-09-27 2006-05-18 Ranbaxy Lab Ltd Muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
WO2006003587A3 (en) * 2004-07-01 2006-09-14 Ranbaxy Lab Ltd Solid oral dosage forms of azabicyclo derivatives
JP2006527183A (en) * 2004-05-31 2006-11-30 アルミラル プロデスファルマ ソシエダッド アノニマ Combination comprising antimuscarinic agent and beta-adrenergic agonist
WO2007039884A1 (en) 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
WO2007045979A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
WO2007077510A2 (en) 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2007110782A1 (en) 2005-12-30 2007-10-04 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7399779B2 (en) 2002-07-08 2008-07-15 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
WO2008075321A3 (en) * 2006-12-21 2008-08-21 Ranbaxy Lab Ltd Modified-release formulations of azabicyclo derivatives
US7446123B2 (en) 2003-04-11 2008-11-04 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP2130830A1 (en) 2008-06-03 2009-12-09 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP2011157358A (en) * 2003-10-14 2011-08-18 Pfizer Products Inc Bicyclic [3.1.0] derivative as glycine transporter inhibitor
CN110191709A (en) * 2017-01-17 2019-08-30 德州大学系统董事会 It can be used as the compound of indole amine 2,3-dioxygenase and/or tryptophan dioxygenase inhibitor
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746998A1 (en) * 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Combination therapy for lower urinary tract symptoms
WO2006016245A1 (en) * 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006054162A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
JP2013542929A (en) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド New bicyclo ring compounds
CN111317754B (en) * 2018-12-13 2022-02-18 泰州医药城国科化物生物医药科技有限公司 Preparation method and application of asiatic moonseed total alkali

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0863141A1 (en) * 1995-10-13 1998-09-09 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
WO2002004402A1 (en) * 2000-07-11 2002-01-17 Banyu Pharmaceutical Co., Ltd. Ester derivatives
WO2002051841A1 (en) * 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490714A (en) 1947-05-13 1949-12-06 Du Pont Preparation of diazoacetic esters
NL267508A (en) 1960-07-26
SE8800207D0 (en) 1988-01-22 1988-01-22 Kabivitrum Ab NEW AMINES, THEIR USE AND MANUFACTURING
US5001160A (en) 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
IE66202B1 (en) 1989-08-16 1995-12-13 Pfizer Azabicyclo quinolone carboxylic acids
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5281601A (en) 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
FR2659323B1 (en) 1990-03-07 1992-06-12 Synthelabo DERIVATIVES OF 4- (AMINOMETHYL) PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
JPH0492921A (en) 1990-08-03 1992-03-25 Fujitsu Ltd Exponential function computing element
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (en) 1992-02-18 1997-09-15 Favorit Oy composting
JPH0635958A (en) 1992-07-14 1994-02-10 Hitachi Ltd Word search method
JP3429338B2 (en) 1992-07-27 2003-07-22 杏林製薬株式会社 Novel arylglycinamide derivative and method for producing the same
JPH06135958A (en) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd Benzocycloheptene derivative and its production
SE9203318D0 (en) 1992-11-06 1992-11-06 Kabi Pharmacia Ab NOVEL 3,3-DIPHENYL PROPYLAMINES, THEIR USE AND PREPARATION
EP0613232B1 (en) 1993-02-24 1997-04-23 Siemens Aktiengesellschaft Flyback converter power supply with a semi-conductor switch of low resistance voltage
NO2005012I1 (en) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin and pharmaceutically acceptable salts thereof
EP0823423B1 (en) * 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
CA2179574A1 (en) 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
WO1997045414A1 (en) 1996-05-31 1997-12-04 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
WO1998000109A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,r)-glycopyrrolate
EP0909172A4 (en) 1996-07-01 1999-06-09 Sepracor Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF URININE CONTINENCE USING ENANTIOMER-ENRICHED (R, S) -GLYCOPYRROLATE
WO1998000016A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
WO1998000133A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,s)-glycopyrrolate
PE92198A1 (en) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd DERIVATIVES OF FLUORINE-CONTAINED 1,4-PIPERIDINE
KR20000057548A (en) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 Optically transmissive material and bond
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc Heterocyclic amides as cell adhesion inhibitors
US6319920B1 (en) 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
AU783095B2 (en) 1999-12-07 2005-09-22 Theravance Biopharma R&D Ip, Llc Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (en) 1999-12-07 2005-08-15 Тераванс, Інк. Urea derivatives, a pharmaceutical composition and use of derivative in the preparation of medicament for the treatment of disease being mediated by muscarine receptor
SE9904765D0 (en) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically useful compounds
WO2001090082A1 (en) 2000-05-25 2001-11-29 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
PL204753B1 (en) 2000-05-25 2010-02-26 Hoffmann La Roche Substituted 1−aminoalkyl−lactams and their use as muscarinic receptor antagonists
WO2002006241A1 (en) 2000-06-14 2002-01-24 Muscagen Limited 1, 2, 3, 5 -tetrahydrobenzo`c!azepin-4-one derivatives having muscarinic antagonist activity
CZ294251B6 (en) 2000-06-27 2004-11-10 Laboratorios S. A. L. V. A. T., S. A. Carbamates and their use in the preparation of a pharmaceutical composition
IL156558A0 (en) 2000-12-28 2004-01-04 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
US6699866B2 (en) 2001-04-17 2004-03-02 Sepracor Inc. Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
JP2005512974A (en) 2001-10-17 2005-05-12 ユ セ ベ ソシエテ アノニム Quinuclidine derivatives, process for their preparation and their use as m2 and / or m3 muscarinic receptor inhibitors
WO2003048124A1 (en) 2001-12-03 2003-06-12 F. Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
MXPA04005313A (en) 2001-12-03 2004-09-13 Hoffmann La Roche Aminotetralin derivatives as muscarinic receptor antagonists.
AU2002345266B2 (en) 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
HK1079787A1 (en) 2002-07-31 2006-04-13 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
HK1079708A1 (en) 2002-08-09 2006-04-13 Ranbaxy Laboratories, Ltd. 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonist
JP2006501236A (en) * 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives containing fluoro and sulfonylamino as muscarinic receptor antagonists
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
WO2004056810A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Xanthine derivatives as muscarinic receptor antagonists
EP1581522B1 (en) 2002-12-23 2008-02-20 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003205964A1 (en) 2003-02-07 2004-08-30 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
DE60313898T2 (en) 2003-04-10 2008-01-17 Ranbaxy Laboratories, Ltd. SUBSTITUTED AZABICYCLO HEXANES DERIVATIVES AS MUSCARIN RECEPTOR ANTAGONISTS
AU2003223010A1 (en) 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009387B1 (en) 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Azabicycloderivatives as muscarinic receptor antagonists
FR2855805B1 (en) 2003-06-06 2005-08-05 Vallourec Vitry STRUCTURE ELEMENT FOR VEHICLE CAPABLE OF IMPROVED SHOCK BEHAVIOR
EP1746998A1 (en) 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Combination therapy for lower urinary tract symptoms
EP1796667A2 (en) 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006064304A1 (en) 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0863141A1 (en) * 1995-10-13 1998-09-09 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
WO2002004402A1 (en) * 2000-07-11 2002-01-17 Banyu Pharmaceutical Co., Ltd. Ester derivatives
WO2002051841A1 (en) * 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544708B2 (en) 2002-07-08 2009-06-09 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
US7399779B2 (en) 2002-07-08 2008-07-15 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
EP1572648B1 (en) * 2002-12-10 2008-07-09 Ranbaxy Laboratories, Ltd. 3,6-disubstituted azabicyclo (3.1.0)-hexane derivatives as muscarinic receptor antagonists
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7446123B2 (en) 2003-04-11 2008-11-04 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
JP2011157358A (en) * 2003-10-14 2011-08-18 Pfizer Products Inc Bicyclic [3.1.0] derivative as glycine transporter inhibitor
JP2006527183A (en) * 2004-05-31 2006-11-30 アルミラル プロデスファルマ ソシエダッド アノニマ Combination comprising antimuscarinic agent and beta-adrenergic agonist
JP4928258B2 (en) * 2004-05-31 2012-05-09 アルミラル・ソシエダッド・アノニマ Combination comprising antimuscarinic agent and beta-adrenergic agonist
JP2012012407A (en) * 2004-05-31 2012-01-19 Almirall Sa Combination comprising antimuscarinic agent and beta-adrenergic agonist
WO2006003587A3 (en) * 2004-07-01 2006-09-14 Ranbaxy Lab Ltd Solid oral dosage forms of azabicyclo derivatives
WO2006032994A3 (en) * 2004-09-24 2006-05-04 Ranbaxy Lab Ltd Muscarinic receptor antagonists
WO2006035282A3 (en) * 2004-09-27 2006-05-18 Ranbaxy Lab Ltd Muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
WO2007039884A1 (en) 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
WO2007045979A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2007110782A1 (en) 2005-12-30 2007-10-04 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2007077510A2 (en) 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2008075321A3 (en) * 2006-12-21 2008-08-21 Ranbaxy Lab Ltd Modified-release formulations of azabicyclo derivatives
EP2130830A1 (en) 2008-06-03 2009-12-09 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CN110191709A (en) * 2017-01-17 2019-08-30 德州大学系统董事会 It can be used as the compound of indole amine 2,3-dioxygenase and/or tryptophan dioxygenase inhibitor
EP3570832A4 (en) * 2017-01-17 2020-06-10 Board Of Regents, The University Of Texas System NOVEL COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND / OR TRYPTOPHANE DIOXYGENASE
US11173145B2 (en) 2017-01-17 2021-11-16 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase

Also Published As

Publication number Publication date
EA200500172A1 (en) 2005-08-25
AU2002345266A1 (en) 2004-01-23
SI1551803T1 (en) 2007-02-28
ZA200500951B (en) 2006-07-26
US20070004791A1 (en) 2007-01-04
HK1079783A1 (en) 2006-04-13
EP1546099A4 (en) 2006-08-02
PT1551803E (en) 2007-01-31
EP1546099B1 (en) 2008-12-31
NZ537585A (en) 2006-07-28
EA009942B1 (en) 2008-04-28
HK1082728A1 (en) 2006-06-16
DE60309057D1 (en) 2006-11-23
BR0312572A (en) 2005-05-10
BR0215801A (en) 2005-05-10
DK1551803T3 (en) 2007-02-19
ATE342253T1 (en) 2006-11-15
EP1551803A1 (en) 2005-07-13
EP1546099A2 (en) 2005-06-29
ATE419236T1 (en) 2009-01-15
EA200500173A1 (en) 2005-08-25
CY1105879T1 (en) 2011-02-02
NZ537584A (en) 2006-07-28
CA2492121A1 (en) 2004-01-15
EP1551803B1 (en) 2006-10-11
EP1551803B8 (en) 2006-12-13
JP2005535655A (en) 2005-11-24
AU2003226579B2 (en) 2009-01-22
US7544708B2 (en) 2009-06-09
AU2002345266B2 (en) 2009-07-02
WO2004004629A3 (en) 2004-05-21
ES2274275T3 (en) 2007-05-16
JP2006502985A (en) 2006-01-26
EA007932B1 (en) 2007-02-27
AU2003226579A1 (en) 2004-01-23
WO2004004629A2 (en) 2004-01-15
EA200501595A1 (en) 2006-06-30
CN1668585A (en) 2005-09-14
MXPA05000435A (en) 2005-04-19
MXPA05000434A (en) 2005-04-19
CN1681784A (en) 2005-10-12
DE60230683D1 (en) 2009-02-12
US7399779B2 (en) 2008-07-15
US20060111425A1 (en) 2006-05-25
CN100519526C (en) 2009-07-29
CA2491998A1 (en) 2004-01-15
DE60309057T2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
US7544708B2 (en) Azabicyclo derivatives as muscarinic receptor antagonists
US7446123B2 (en) Azabicyclo derivatives as muscarinic receptor antagonists
AU2003214535B2 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20070010568A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7560479B2 (en) 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
HK1082728B (en) Azabicyclo derivatives as muscarinic receptor antagonists
KR20050023400A (en) Azabicyclo derivatives as muscarinic receptor antagonists
HK1079783B (en) 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
KR20050023401A (en) 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2491998

Country of ref document: CA

Ref document number: PA/a/2005/000435

Country of ref document: MX

Ref document number: 537585

Country of ref document: NZ

Ref document number: 2004519035

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057000402

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003226579

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003762827

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005/00951

Country of ref document: ZA

Ref document number: 405/DELNP/2005

Country of ref document: IN

Ref document number: 200500951

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 200500172

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038211300

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057000402

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003762827

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006111425

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10520572

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10520572

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003762827

Country of ref document: EP